[
    {
        "molecule_name": "PRD-1177",
        "protein_target_name": "myostatin",
        "binding_metric": "Kd",
        "value": "250",
        "unit": "pM",
        "is_logarithmic": false,
        "raw_mentions": "Here are the extracted sentences/rows that meet the criteria:\n\n\nThe global Kd analysis shown in Table 13 gives a Kd of 170 pM with a 95% confidence interval of 330-60 pM.\nThese analyses indicate that PRD-1177 binds myostatin with a global Kd value of 250 pM and a 95% confidence interval of 340-130 pM (Table 13).\nATI-1338 binds myostatin with a global Kd value of 850 pM and a 95% confidence interval of 1400-330 pM.\nTABLE 13: Adnectin\tKd\tKd high\tKd low\tPRD-1474\t170 pM\t330 pM\t60 pM\nTABLE 13: Adnectin\tKd\tKd high\tKd low\tPRD-1177\t250 pM\t340 pM\t130 pM\nTABLE 13: Adnectin\tKd\tKd high\tKd low\tATI-1338\t850 pM\t1400 pM\t330 pM\nIn the HTRF competition binding assay, potencies ranged from IC50=1.5 nM to >100 nM (Table 14).\nMost positions tolerated alanine substitution in the HTRF assay to some degree, with the exception of Gly55, Arg56, and Gly57 of the DE loop, for which binding was drastically reduced (IC50s>100 nM).\nA lesser effect occurred in positions Gly30 of the BC loop, and Val80, Thr81, and Tyr88 of the FG loop, which still showed binding but with a >10-fold increase in IC50 relative to the parental sequence (“WT”).\nIn the ARE-luciferase cell-based assay, potency of mutants ranged from IC50=0.6 nM to >100 nM (Table 14).\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tWT parent\t1\t0.3\t0.6\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tBC\tS25A\t1\t0.82\t2.9\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tBC\tL26A\t1\t2.3\t16\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tBC\tP27A\t1\t1.0\t10\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tBC\tH28A\t1\t0.86\t6.2\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tBC\tQ29A\t1\t0.71\t1.5\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tBC\tG30A\t2\t5\t14.0\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tBC\tK31A\t1\t0.62\t2.2\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tBC\tN33A\t1\t2.09\t9.8\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tDE\tG55A\t2\t>100\t>100\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tDE\tR56A\t1\t55\t>100\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tDE\tG57A\t1\t>100\t>100\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tDE\tV58A\t2\t1.63\t3.3\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tFG\tV80A\t1\t14.0\t>100\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tFG\tT81A\t1\t4.93\t2.0\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tFG\tD82A\t1\t0.81\t1.8\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tFG\tT83A\t1\t1.31\t1.8\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tFG\tG84A\t1\t2.03\t3.6\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tFG\tY85A\t1\t2.05\t5.5\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tFG\tL86A\t2\t1.41\t2.0\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tFG\tK87A\t1\t0.82\t2.0\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tFG\tY88A\t1\t11\t>100\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tFG\tK89A\t1\t0.71\t1.6"
    },
    {
        "molecule_name": "ATI-1338",
        "protein_target_name": "myostatin",
        "binding_metric": "Kd",
        "value": "850",
        "unit": "pM",
        "is_logarithmic": false,
        "raw_mentions": "Here are the extracted sentences/rows that meet the criteria:\n\n\nThe global Kd analysis shown in Table 13 gives a Kd of 170 pM with a 95% confidence interval of 330-60 pM.\nThese analyses indicate that PRD-1177 binds myostatin with a global Kd value of 250 pM and a 95% confidence interval of 340-130 pM (Table 13).\nATI-1338 binds myostatin with a global Kd value of 850 pM and a 95% confidence interval of 1400-330 pM.\nTABLE 13: Adnectin\tKd\tKd high\tKd low\tPRD-1474\t170 pM\t330 pM\t60 pM\nTABLE 13: Adnectin\tKd\tKd high\tKd low\tPRD-1177\t250 pM\t340 pM\t130 pM\nTABLE 13: Adnectin\tKd\tKd high\tKd low\tATI-1338\t850 pM\t1400 pM\t330 pM\nIn the HTRF competition binding assay, potencies ranged from IC50=1.5 nM to >100 nM (Table 14).\nMost positions tolerated alanine substitution in the HTRF assay to some degree, with the exception of Gly55, Arg56, and Gly57 of the DE loop, for which binding was drastically reduced (IC50s>100 nM).\nA lesser effect occurred in positions Gly30 of the BC loop, and Val80, Thr81, and Tyr88 of the FG loop, which still showed binding but with a >10-fold increase in IC50 relative to the parental sequence (“WT”).\nIn the ARE-luciferase cell-based assay, potency of mutants ranged from IC50=0.6 nM to >100 nM (Table 14).\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tWT parent\t1\t0.3\t0.6\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tBC\tS25A\t1\t0.82\t2.9\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tBC\tL26A\t1\t2.3\t16\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tBC\tP27A\t1\t1.0\t10\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tBC\tH28A\t1\t0.86\t6.2\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tBC\tQ29A\t1\t0.71\t1.5\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tBC\tG30A\t2\t5\t14.0\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tBC\tK31A\t1\t0.62\t2.2\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tBC\tN33A\t1\t2.09\t9.8\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tDE\tG55A\t2\t>100\t>100\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tDE\tR56A\t1\t55\t>100\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tDE\tG57A\t1\t>100\t>100\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tDE\tV58A\t2\t1.63\t3.3\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tFG\tV80A\t1\t14.0\t>100\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tFG\tT81A\t1\t4.93\t2.0\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tFG\tD82A\t1\t0.81\t1.8\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tFG\tT83A\t1\t1.31\t1.8\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tFG\tG84A\t1\t2.03\t3.6\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tFG\tY85A\t1\t2.05\t5.5\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tFG\tL86A\t2\t1.41\t2.0\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tFG\tK87A\t1\t0.82\t2.0\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tFG\tY88A\t1\t11\t>100\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tFG\tK89A\t1\t0.71\t1.6"
    },
    {
        "molecule_name": "WT parent",
        "protein_target_name": "myostatin",
        "binding_metric": "IC50",
        "value": "0.3",
        "unit": "nM",
        "is_logarithmic": false,
        "raw_mentions": "Here are the extracted sentences/rows that meet the criteria:\n\n\nThe global Kd analysis shown in Table 13 gives a Kd of 170 pM with a 95% confidence interval of 330-60 pM.\nThese analyses indicate that PRD-1177 binds myostatin with a global Kd value of 250 pM and a 95% confidence interval of 340-130 pM (Table 13).\nATI-1338 binds myostatin with a global Kd value of 850 pM and a 95% confidence interval of 1400-330 pM.\nTABLE 13: Adnectin\tKd\tKd high\tKd low\tPRD-1474\t170 pM\t330 pM\t60 pM\nTABLE 13: Adnectin\tKd\tKd high\tKd low\tPRD-1177\t250 pM\t340 pM\t130 pM\nTABLE 13: Adnectin\tKd\tKd high\tKd low\tATI-1338\t850 pM\t1400 pM\t330 pM\nIn the HTRF competition binding assay, potencies ranged from IC50=1.5 nM to >100 nM (Table 14).\nMost positions tolerated alanine substitution in the HTRF assay to some degree, with the exception of Gly55, Arg56, and Gly57 of the DE loop, for which binding was drastically reduced (IC50s>100 nM).\nA lesser effect occurred in positions Gly30 of the BC loop, and Val80, Thr81, and Tyr88 of the FG loop, which still showed binding but with a >10-fold increase in IC50 relative to the parental sequence (“WT”).\nIn the ARE-luciferase cell-based assay, potency of mutants ranged from IC50=0.6 nM to >100 nM (Table 14).\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tWT parent\t1\t0.3\t0.6\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tBC\tS25A\t1\t0.82\t2.9\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tBC\tL26A\t1\t2.3\t16\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tBC\tP27A\t1\t1.0\t10\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tBC\tH28A\t1\t0.86\t6.2\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tBC\tQ29A\t1\t0.71\t1.5\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tBC\tG30A\t2\t5\t14.0\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tBC\tK31A\t1\t0.62\t2.2\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tBC\tN33A\t1\t2.09\t9.8\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tDE\tG55A\t2\t>100\t>100\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tDE\tR56A\t1\t55\t>100\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tDE\tG57A\t1\t>100\t>100\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tDE\tV58A\t2\t1.63\t3.3\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tFG\tV80A\t1\t14.0\t>100\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tFG\tT81A\t1\t4.93\t2.0\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tFG\tD82A\t1\t0.81\t1.8\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tFG\tT83A\t1\t1.31\t1.8\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tFG\tG84A\t1\t2.03\t3.6\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tFG\tY85A\t1\t2.05\t5.5\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tFG\tL86A\t2\t1.41\t2.0\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tFG\tK87A\t1\t0.82\t2.0\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tFG\tY88A\t1\t11\t>100\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tFG\tK89A\t1\t0.71\t1.6"
    },
    {
        "molecule_name": "WT parent",
        "protein_target_name": "myostatin",
        "binding_metric": "IC50",
        "value": "0.6",
        "unit": "nM",
        "is_logarithmic": false,
        "raw_mentions": "Here are the extracted sentences/rows that meet the criteria:\n\n\nThe global Kd analysis shown in Table 13 gives a Kd of 170 pM with a 95% confidence interval of 330-60 pM.\nThese analyses indicate that PRD-1177 binds myostatin with a global Kd value of 250 pM and a 95% confidence interval of 340-130 pM (Table 13).\nATI-1338 binds myostatin with a global Kd value of 850 pM and a 95% confidence interval of 1400-330 pM.\nTABLE 13: Adnectin\tKd\tKd high\tKd low\tPRD-1474\t170 pM\t330 pM\t60 pM\nTABLE 13: Adnectin\tKd\tKd high\tKd low\tPRD-1177\t250 pM\t340 pM\t130 pM\nTABLE 13: Adnectin\tKd\tKd high\tKd low\tATI-1338\t850 pM\t1400 pM\t330 pM\nIn the HTRF competition binding assay, potencies ranged from IC50=1.5 nM to >100 nM (Table 14).\nMost positions tolerated alanine substitution in the HTRF assay to some degree, with the exception of Gly55, Arg56, and Gly57 of the DE loop, for which binding was drastically reduced (IC50s>100 nM).\nA lesser effect occurred in positions Gly30 of the BC loop, and Val80, Thr81, and Tyr88 of the FG loop, which still showed binding but with a >10-fold increase in IC50 relative to the parental sequence (“WT”).\nIn the ARE-luciferase cell-based assay, potency of mutants ranged from IC50=0.6 nM to >100 nM (Table 14).\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tWT parent\t1\t0.3\t0.6\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tBC\tS25A\t1\t0.82\t2.9\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tBC\tL26A\t1\t2.3\t16\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tBC\tP27A\t1\t1.0\t10\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tBC\tH28A\t1\t0.86\t6.2\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tBC\tQ29A\t1\t0.71\t1.5\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tBC\tG30A\t2\t5\t14.0\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tBC\tK31A\t1\t0.62\t2.2\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tBC\tN33A\t1\t2.09\t9.8\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tDE\tG55A\t2\t>100\t>100\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tDE\tR56A\t1\t55\t>100\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tDE\tG57A\t1\t>100\t>100\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tDE\tV58A\t2\t1.63\t3.3\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tFG\tV80A\t1\t14.0\t>100\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tFG\tT81A\t1\t4.93\t2.0\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tFG\tD82A\t1\t0.81\t1.8\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tFG\tT83A\t1\t1.31\t1.8\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tFG\tG84A\t1\t2.03\t3.6\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tFG\tY85A\t1\t2.05\t5.5\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tFG\tL86A\t2\t1.41\t2.0\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tFG\tK87A\t1\t0.82\t2.0\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tFG\tY88A\t1\t11\t>100\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tFG\tK89A\t1\t0.71\t1.6"
    },
    {
        "molecule_name": "S25A",
        "protein_target_name": "myostatin",
        "binding_metric": "IC50",
        "value": "0.82",
        "unit": "nM",
        "is_logarithmic": false,
        "raw_mentions": "Here are the extracted sentences/rows that meet the criteria:\n\n\nThe global Kd analysis shown in Table 13 gives a Kd of 170 pM with a 95% confidence interval of 330-60 pM.\nThese analyses indicate that PRD-1177 binds myostatin with a global Kd value of 250 pM and a 95% confidence interval of 340-130 pM (Table 13).\nATI-1338 binds myostatin with a global Kd value of 850 pM and a 95% confidence interval of 1400-330 pM.\nTABLE 13: Adnectin\tKd\tKd high\tKd low\tPRD-1474\t170 pM\t330 pM\t60 pM\nTABLE 13: Adnectin\tKd\tKd high\tKd low\tPRD-1177\t250 pM\t340 pM\t130 pM\nTABLE 13: Adnectin\tKd\tKd high\tKd low\tATI-1338\t850 pM\t1400 pM\t330 pM\nIn the HTRF competition binding assay, potencies ranged from IC50=1.5 nM to >100 nM (Table 14).\nMost positions tolerated alanine substitution in the HTRF assay to some degree, with the exception of Gly55, Arg56, and Gly57 of the DE loop, for which binding was drastically reduced (IC50s>100 nM).\nA lesser effect occurred in positions Gly30 of the BC loop, and Val80, Thr81, and Tyr88 of the FG loop, which still showed binding but with a >10-fold increase in IC50 relative to the parental sequence (“WT”).\nIn the ARE-luciferase cell-based assay, potency of mutants ranged from IC50=0.6 nM to >100 nM (Table 14).\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tWT parent\t1\t0.3\t0.6\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tBC\tS25A\t1\t0.82\t2.9\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tBC\tL26A\t1\t2.3\t16\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tBC\tP27A\t1\t1.0\t10\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tBC\tH28A\t1\t0.86\t6.2\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tBC\tQ29A\t1\t0.71\t1.5\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tBC\tG30A\t2\t5\t14.0\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tBC\tK31A\t1\t0.62\t2.2\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tBC\tN33A\t1\t2.09\t9.8\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tDE\tG55A\t2\t>100\t>100\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tDE\tR56A\t1\t55\t>100\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tDE\tG57A\t1\t>100\t>100\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tDE\tV58A\t2\t1.63\t3.3\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tFG\tV80A\t1\t14.0\t>100\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tFG\tT81A\t1\t4.93\t2.0\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tFG\tD82A\t1\t0.81\t1.8\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tFG\tT83A\t1\t1.31\t1.8\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tFG\tG84A\t1\t2.03\t3.6\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tFG\tY85A\t1\t2.05\t5.5\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tFG\tL86A\t2\t1.41\t2.0\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tFG\tK87A\t1\t0.82\t2.0\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tFG\tY88A\t1\t11\t>100\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tFG\tK89A\t1\t0.71\t1.6"
    },
    {
        "molecule_name": "S25A",
        "protein_target_name": "myostatin",
        "binding_metric": "IC50",
        "value": "2.9",
        "unit": "nM",
        "is_logarithmic": false,
        "raw_mentions": "Here are the extracted sentences/rows that meet the criteria:\n\n\nThe global Kd analysis shown in Table 13 gives a Kd of 170 pM with a 95% confidence interval of 330-60 pM.\nThese analyses indicate that PRD-1177 binds myostatin with a global Kd value of 250 pM and a 95% confidence interval of 340-130 pM (Table 13).\nATI-1338 binds myostatin with a global Kd value of 850 pM and a 95% confidence interval of 1400-330 pM.\nTABLE 13: Adnectin\tKd\tKd high\tKd low\tPRD-1474\t170 pM\t330 pM\t60 pM\nTABLE 13: Adnectin\tKd\tKd high\tKd low\tPRD-1177\t250 pM\t340 pM\t130 pM\nTABLE 13: Adnectin\tKd\tKd high\tKd low\tATI-1338\t850 pM\t1400 pM\t330 pM\nIn the HTRF competition binding assay, potencies ranged from IC50=1.5 nM to >100 nM (Table 14).\nMost positions tolerated alanine substitution in the HTRF assay to some degree, with the exception of Gly55, Arg56, and Gly57 of the DE loop, for which binding was drastically reduced (IC50s>100 nM).\nA lesser effect occurred in positions Gly30 of the BC loop, and Val80, Thr81, and Tyr88 of the FG loop, which still showed binding but with a >10-fold increase in IC50 relative to the parental sequence (“WT”).\nIn the ARE-luciferase cell-based assay, potency of mutants ranged from IC50=0.6 nM to >100 nM (Table 14).\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tWT parent\t1\t0.3\t0.6\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tBC\tS25A\t1\t0.82\t2.9\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tBC\tL26A\t1\t2.3\t16\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tBC\tP27A\t1\t1.0\t10\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tBC\tH28A\t1\t0.86\t6.2\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tBC\tQ29A\t1\t0.71\t1.5\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tBC\tG30A\t2\t5\t14.0\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tBC\tK31A\t1\t0.62\t2.2\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tBC\tN33A\t1\t2.09\t9.8\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tDE\tG55A\t2\t>100\t>100\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tDE\tR56A\t1\t55\t>100\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tDE\tG57A\t1\t>100\t>100\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tDE\tV58A\t2\t1.63\t3.3\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tFG\tV80A\t1\t14.0\t>100\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tFG\tT81A\t1\t4.93\t2.0\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tFG\tD82A\t1\t0.81\t1.8\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tFG\tT83A\t1\t1.31\t1.8\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tFG\tG84A\t1\t2.03\t3.6\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tFG\tY85A\t1\t2.05\t5.5\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tFG\tL86A\t2\t1.41\t2.0\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tFG\tK87A\t1\t0.82\t2.0\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tFG\tY88A\t1\t11\t>100\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tFG\tK89A\t1\t0.71\t1.6"
    },
    {
        "molecule_name": "L26A",
        "protein_target_name": "myostatin",
        "binding_metric": "IC50",
        "value": "2.3",
        "unit": "nM",
        "is_logarithmic": false,
        "raw_mentions": "Here are the extracted sentences/rows that meet the criteria:\n\n\nThe global Kd analysis shown in Table 13 gives a Kd of 170 pM with a 95% confidence interval of 330-60 pM.\nThese analyses indicate that PRD-1177 binds myostatin with a global Kd value of 250 pM and a 95% confidence interval of 340-130 pM (Table 13).\nATI-1338 binds myostatin with a global Kd value of 850 pM and a 95% confidence interval of 1400-330 pM.\nTABLE 13: Adnectin\tKd\tKd high\tKd low\tPRD-1474\t170 pM\t330 pM\t60 pM\nTABLE 13: Adnectin\tKd\tKd high\tKd low\tPRD-1177\t250 pM\t340 pM\t130 pM\nTABLE 13: Adnectin\tKd\tKd high\tKd low\tATI-1338\t850 pM\t1400 pM\t330 pM\nIn the HTRF competition binding assay, potencies ranged from IC50=1.5 nM to >100 nM (Table 14).\nMost positions tolerated alanine substitution in the HTRF assay to some degree, with the exception of Gly55, Arg56, and Gly57 of the DE loop, for which binding was drastically reduced (IC50s>100 nM).\nA lesser effect occurred in positions Gly30 of the BC loop, and Val80, Thr81, and Tyr88 of the FG loop, which still showed binding but with a >10-fold increase in IC50 relative to the parental sequence (“WT”).\nIn the ARE-luciferase cell-based assay, potency of mutants ranged from IC50=0.6 nM to >100 nM (Table 14).\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tWT parent\t1\t0.3\t0.6\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tBC\tS25A\t1\t0.82\t2.9\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tBC\tL26A\t1\t2.3\t16\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tBC\tP27A\t1\t1.0\t10\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tBC\tH28A\t1\t0.86\t6.2\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tBC\tQ29A\t1\t0.71\t1.5\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tBC\tG30A\t2\t5\t14.0\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tBC\tK31A\t1\t0.62\t2.2\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tBC\tN33A\t1\t2.09\t9.8\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tDE\tG55A\t2\t>100\t>100\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tDE\tR56A\t1\t55\t>100\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tDE\tG57A\t1\t>100\t>100\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tDE\tV58A\t2\t1.63\t3.3\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tFG\tV80A\t1\t14.0\t>100\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tFG\tT81A\t1\t4.93\t2.0\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tFG\tD82A\t1\t0.81\t1.8\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tFG\tT83A\t1\t1.31\t1.8\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tFG\tG84A\t1\t2.03\t3.6\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tFG\tY85A\t1\t2.05\t5.5\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tFG\tL86A\t2\t1.41\t2.0\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tFG\tK87A\t1\t0.82\t2.0\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tFG\tY88A\t1\t11\t>100\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tFG\tK89A\t1\t0.71\t1.6"
    },
    {
        "molecule_name": "L26A",
        "protein_target_name": "myostatin",
        "binding_metric": "IC50",
        "value": "16",
        "unit": "nM",
        "is_logarithmic": false,
        "raw_mentions": "Here are the extracted sentences/rows that meet the criteria:\n\n\nThe global Kd analysis shown in Table 13 gives a Kd of 170 pM with a 95% confidence interval of 330-60 pM.\nThese analyses indicate that PRD-1177 binds myostatin with a global Kd value of 250 pM and a 95% confidence interval of 340-130 pM (Table 13).\nATI-1338 binds myostatin with a global Kd value of 850 pM and a 95% confidence interval of 1400-330 pM.\nTABLE 13: Adnectin\tKd\tKd high\tKd low\tPRD-1474\t170 pM\t330 pM\t60 pM\nTABLE 13: Adnectin\tKd\tKd high\tKd low\tPRD-1177\t250 pM\t340 pM\t130 pM\nTABLE 13: Adnectin\tKd\tKd high\tKd low\tATI-1338\t850 pM\t1400 pM\t330 pM\nIn the HTRF competition binding assay, potencies ranged from IC50=1.5 nM to >100 nM (Table 14).\nMost positions tolerated alanine substitution in the HTRF assay to some degree, with the exception of Gly55, Arg56, and Gly57 of the DE loop, for which binding was drastically reduced (IC50s>100 nM).\nA lesser effect occurred in positions Gly30 of the BC loop, and Val80, Thr81, and Tyr88 of the FG loop, which still showed binding but with a >10-fold increase in IC50 relative to the parental sequence (“WT”).\nIn the ARE-luciferase cell-based assay, potency of mutants ranged from IC50=0.6 nM to >100 nM (Table 14).\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tWT parent\t1\t0.3\t0.6\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tBC\tS25A\t1\t0.82\t2.9\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tBC\tL26A\t1\t2.3\t16\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tBC\tP27A\t1\t1.0\t10\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tBC\tH28A\t1\t0.86\t6.2\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tBC\tQ29A\t1\t0.71\t1.5\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tBC\tG30A\t2\t5\t14.0\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tBC\tK31A\t1\t0.62\t2.2\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tBC\tN33A\t1\t2.09\t9.8\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tDE\tG55A\t2\t>100\t>100\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tDE\tR56A\t1\t55\t>100\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tDE\tG57A\t1\t>100\t>100\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tDE\tV58A\t2\t1.63\t3.3\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tFG\tV80A\t1\t14.0\t>100\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tFG\tT81A\t1\t4.93\t2.0\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tFG\tD82A\t1\t0.81\t1.8\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tFG\tT83A\t1\t1.31\t1.8\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tFG\tG84A\t1\t2.03\t3.6\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tFG\tY85A\t1\t2.05\t5.5\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tFG\tL86A\t2\t1.41\t2.0\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tFG\tK87A\t1\t0.82\t2.0\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tFG\tY88A\t1\t11\t>100\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tFG\tK89A\t1\t0.71\t1.6"
    },
    {
        "molecule_name": "P27A",
        "protein_target_name": "myostatin",
        "binding_metric": "IC50",
        "value": "1.0",
        "unit": "nM",
        "is_logarithmic": false,
        "raw_mentions": "Here are the extracted sentences/rows that meet the criteria:\n\n\nThe global Kd analysis shown in Table 13 gives a Kd of 170 pM with a 95% confidence interval of 330-60 pM.\nThese analyses indicate that PRD-1177 binds myostatin with a global Kd value of 250 pM and a 95% confidence interval of 340-130 pM (Table 13).\nATI-1338 binds myostatin with a global Kd value of 850 pM and a 95% confidence interval of 1400-330 pM.\nTABLE 13: Adnectin\tKd\tKd high\tKd low\tPRD-1474\t170 pM\t330 pM\t60 pM\nTABLE 13: Adnectin\tKd\tKd high\tKd low\tPRD-1177\t250 pM\t340 pM\t130 pM\nTABLE 13: Adnectin\tKd\tKd high\tKd low\tATI-1338\t850 pM\t1400 pM\t330 pM\nIn the HTRF competition binding assay, potencies ranged from IC50=1.5 nM to >100 nM (Table 14).\nMost positions tolerated alanine substitution in the HTRF assay to some degree, with the exception of Gly55, Arg56, and Gly57 of the DE loop, for which binding was drastically reduced (IC50s>100 nM).\nA lesser effect occurred in positions Gly30 of the BC loop, and Val80, Thr81, and Tyr88 of the FG loop, which still showed binding but with a >10-fold increase in IC50 relative to the parental sequence (“WT”).\nIn the ARE-luciferase cell-based assay, potency of mutants ranged from IC50=0.6 nM to >100 nM (Table 14).\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tWT parent\t1\t0.3\t0.6\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tBC\tS25A\t1\t0.82\t2.9\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tBC\tL26A\t1\t2.3\t16\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tBC\tP27A\t1\t1.0\t10\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tBC\tH28A\t1\t0.86\t6.2\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tBC\tQ29A\t1\t0.71\t1.5\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tBC\tG30A\t2\t5\t14.0\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tBC\tK31A\t1\t0.62\t2.2\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tBC\tN33A\t1\t2.09\t9.8\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tDE\tG55A\t2\t>100\t>100\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tDE\tR56A\t1\t55\t>100\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tDE\tG57A\t1\t>100\t>100\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tDE\tV58A\t2\t1.63\t3.3\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tFG\tV80A\t1\t14.0\t>100\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tFG\tT81A\t1\t4.93\t2.0\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tFG\tD82A\t1\t0.81\t1.8\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tFG\tT83A\t1\t1.31\t1.8\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tFG\tG84A\t1\t2.03\t3.6\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tFG\tY85A\t1\t2.05\t5.5\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tFG\tL86A\t2\t1.41\t2.0\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tFG\tK87A\t1\t0.82\t2.0\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tFG\tY88A\t1\t11\t>100\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tFG\tK89A\t1\t0.71\t1.6"
    },
    {
        "molecule_name": "P27A",
        "protein_target_name": "myostatin",
        "binding_metric": "IC50",
        "value": "10",
        "unit": "nM",
        "is_logarithmic": false,
        "raw_mentions": "Here are the extracted sentences/rows that meet the criteria:\n\n\nThe global Kd analysis shown in Table 13 gives a Kd of 170 pM with a 95% confidence interval of 330-60 pM.\nThese analyses indicate that PRD-1177 binds myostatin with a global Kd value of 250 pM and a 95% confidence interval of 340-130 pM (Table 13).\nATI-1338 binds myostatin with a global Kd value of 850 pM and a 95% confidence interval of 1400-330 pM.\nTABLE 13: Adnectin\tKd\tKd high\tKd low\tPRD-1474\t170 pM\t330 pM\t60 pM\nTABLE 13: Adnectin\tKd\tKd high\tKd low\tPRD-1177\t250 pM\t340 pM\t130 pM\nTABLE 13: Adnectin\tKd\tKd high\tKd low\tATI-1338\t850 pM\t1400 pM\t330 pM\nIn the HTRF competition binding assay, potencies ranged from IC50=1.5 nM to >100 nM (Table 14).\nMost positions tolerated alanine substitution in the HTRF assay to some degree, with the exception of Gly55, Arg56, and Gly57 of the DE loop, for which binding was drastically reduced (IC50s>100 nM).\nA lesser effect occurred in positions Gly30 of the BC loop, and Val80, Thr81, and Tyr88 of the FG loop, which still showed binding but with a >10-fold increase in IC50 relative to the parental sequence (“WT”).\nIn the ARE-luciferase cell-based assay, potency of mutants ranged from IC50=0.6 nM to >100 nM (Table 14).\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tWT parent\t1\t0.3\t0.6\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tBC\tS25A\t1\t0.82\t2.9\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tBC\tL26A\t1\t2.3\t16\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tBC\tP27A\t1\t1.0\t10\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tBC\tH28A\t1\t0.86\t6.2\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tBC\tQ29A\t1\t0.71\t1.5\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tBC\tG30A\t2\t5\t14.0\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tBC\tK31A\t1\t0.62\t2.2\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tBC\tN33A\t1\t2.09\t9.8\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tDE\tG55A\t2\t>100\t>100\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tDE\tR56A\t1\t55\t>100\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tDE\tG57A\t1\t>100\t>100\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tDE\tV58A\t2\t1.63\t3.3\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tFG\tV80A\t1\t14.0\t>100\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tFG\tT81A\t1\t4.93\t2.0\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tFG\tD82A\t1\t0.81\t1.8\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tFG\tT83A\t1\t1.31\t1.8\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tFG\tG84A\t1\t2.03\t3.6\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tFG\tY85A\t1\t2.05\t5.5\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tFG\tL86A\t2\t1.41\t2.0\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tFG\tK87A\t1\t0.82\t2.0\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tFG\tY88A\t1\t11\t>100\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tFG\tK89A\t1\t0.71\t1.6"
    },
    {
        "molecule_name": "H28A",
        "protein_target_name": "myostatin",
        "binding_metric": "IC50",
        "value": "0.86",
        "unit": "nM",
        "is_logarithmic": false,
        "raw_mentions": "Here are the extracted sentences/rows that meet the criteria:\n\n\nThe global Kd analysis shown in Table 13 gives a Kd of 170 pM with a 95% confidence interval of 330-60 pM.\nThese analyses indicate that PRD-1177 binds myostatin with a global Kd value of 250 pM and a 95% confidence interval of 340-130 pM (Table 13).\nATI-1338 binds myostatin with a global Kd value of 850 pM and a 95% confidence interval of 1400-330 pM.\nTABLE 13: Adnectin\tKd\tKd high\tKd low\tPRD-1474\t170 pM\t330 pM\t60 pM\nTABLE 13: Adnectin\tKd\tKd high\tKd low\tPRD-1177\t250 pM\t340 pM\t130 pM\nTABLE 13: Adnectin\tKd\tKd high\tKd low\tATI-1338\t850 pM\t1400 pM\t330 pM\nIn the HTRF competition binding assay, potencies ranged from IC50=1.5 nM to >100 nM (Table 14).\nMost positions tolerated alanine substitution in the HTRF assay to some degree, with the exception of Gly55, Arg56, and Gly57 of the DE loop, for which binding was drastically reduced (IC50s>100 nM).\nA lesser effect occurred in positions Gly30 of the BC loop, and Val80, Thr81, and Tyr88 of the FG loop, which still showed binding but with a >10-fold increase in IC50 relative to the parental sequence (“WT”).\nIn the ARE-luciferase cell-based assay, potency of mutants ranged from IC50=0.6 nM to >100 nM (Table 14).\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tWT parent\t1\t0.3\t0.6\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tBC\tS25A\t1\t0.82\t2.9\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tBC\tL26A\t1\t2.3\t16\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tBC\tP27A\t1\t1.0\t10\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tBC\tH28A\t1\t0.86\t6.2\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tBC\tQ29A\t1\t0.71\t1.5\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tBC\tG30A\t2\t5\t14.0\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tBC\tK31A\t1\t0.62\t2.2\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tBC\tN33A\t1\t2.09\t9.8\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tDE\tG55A\t2\t>100\t>100\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tDE\tR56A\t1\t55\t>100\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tDE\tG57A\t1\t>100\t>100\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tDE\tV58A\t2\t1.63\t3.3\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tFG\tV80A\t1\t14.0\t>100\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tFG\tT81A\t1\t4.93\t2.0\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tFG\tD82A\t1\t0.81\t1.8\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tFG\tT83A\t1\t1.31\t1.8\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tFG\tG84A\t1\t2.03\t3.6\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tFG\tY85A\t1\t2.05\t5.5\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tFG\tL86A\t2\t1.41\t2.0\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tFG\tK87A\t1\t0.82\t2.0\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tFG\tY88A\t1\t11\t>100\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tFG\tK89A\t1\t0.71\t1.6"
    },
    {
        "molecule_name": "H28A",
        "protein_target_name": "myostatin",
        "binding_metric": "IC50",
        "value": "6.2",
        "unit": "nM",
        "is_logarithmic": false,
        "raw_mentions": "Here are the extracted sentences/rows that meet the criteria:\n\n\nThe global Kd analysis shown in Table 13 gives a Kd of 170 pM with a 95% confidence interval of 330-60 pM.\nThese analyses indicate that PRD-1177 binds myostatin with a global Kd value of 250 pM and a 95% confidence interval of 340-130 pM (Table 13).\nATI-1338 binds myostatin with a global Kd value of 850 pM and a 95% confidence interval of 1400-330 pM.\nTABLE 13: Adnectin\tKd\tKd high\tKd low\tPRD-1474\t170 pM\t330 pM\t60 pM\nTABLE 13: Adnectin\tKd\tKd high\tKd low\tPRD-1177\t250 pM\t340 pM\t130 pM\nTABLE 13: Adnectin\tKd\tKd high\tKd low\tATI-1338\t850 pM\t1400 pM\t330 pM\nIn the HTRF competition binding assay, potencies ranged from IC50=1.5 nM to >100 nM (Table 14).\nMost positions tolerated alanine substitution in the HTRF assay to some degree, with the exception of Gly55, Arg56, and Gly57 of the DE loop, for which binding was drastically reduced (IC50s>100 nM).\nA lesser effect occurred in positions Gly30 of the BC loop, and Val80, Thr81, and Tyr88 of the FG loop, which still showed binding but with a >10-fold increase in IC50 relative to the parental sequence (“WT”).\nIn the ARE-luciferase cell-based assay, potency of mutants ranged from IC50=0.6 nM to >100 nM (Table 14).\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tWT parent\t1\t0.3\t0.6\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tBC\tS25A\t1\t0.82\t2.9\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tBC\tL26A\t1\t2.3\t16\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tBC\tP27A\t1\t1.0\t10\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tBC\tH28A\t1\t0.86\t6.2\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tBC\tQ29A\t1\t0.71\t1.5\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tBC\tG30A\t2\t5\t14.0\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tBC\tK31A\t1\t0.62\t2.2\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tBC\tN33A\t1\t2.09\t9.8\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tDE\tG55A\t2\t>100\t>100\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tDE\tR56A\t1\t55\t>100\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tDE\tG57A\t1\t>100\t>100\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tDE\tV58A\t2\t1.63\t3.3\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tFG\tV80A\t1\t14.0\t>100\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tFG\tT81A\t1\t4.93\t2.0\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tFG\tD82A\t1\t0.81\t1.8\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tFG\tT83A\t1\t1.31\t1.8\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tFG\tG84A\t1\t2.03\t3.6\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tFG\tY85A\t1\t2.05\t5.5\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tFG\tL86A\t2\t1.41\t2.0\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tFG\tK87A\t1\t0.82\t2.0\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tFG\tY88A\t1\t11\t>100\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tFG\tK89A\t1\t0.71\t1.6"
    },
    {
        "molecule_name": "Q29A",
        "protein_target_name": "myostatin",
        "binding_metric": "IC50",
        "value": "0.71",
        "unit": "nM",
        "is_logarithmic": false,
        "raw_mentions": "Here are the extracted sentences/rows that meet the criteria:\n\n\nThe global Kd analysis shown in Table 13 gives a Kd of 170 pM with a 95% confidence interval of 330-60 pM.\nThese analyses indicate that PRD-1177 binds myostatin with a global Kd value of 250 pM and a 95% confidence interval of 340-130 pM (Table 13).\nATI-1338 binds myostatin with a global Kd value of 850 pM and a 95% confidence interval of 1400-330 pM.\nTABLE 13: Adnectin\tKd\tKd high\tKd low\tPRD-1474\t170 pM\t330 pM\t60 pM\nTABLE 13: Adnectin\tKd\tKd high\tKd low\tPRD-1177\t250 pM\t340 pM\t130 pM\nTABLE 13: Adnectin\tKd\tKd high\tKd low\tATI-1338\t850 pM\t1400 pM\t330 pM\nIn the HTRF competition binding assay, potencies ranged from IC50=1.5 nM to >100 nM (Table 14).\nMost positions tolerated alanine substitution in the HTRF assay to some degree, with the exception of Gly55, Arg56, and Gly57 of the DE loop, for which binding was drastically reduced (IC50s>100 nM).\nA lesser effect occurred in positions Gly30 of the BC loop, and Val80, Thr81, and Tyr88 of the FG loop, which still showed binding but with a >10-fold increase in IC50 relative to the parental sequence (“WT”).\nIn the ARE-luciferase cell-based assay, potency of mutants ranged from IC50=0.6 nM to >100 nM (Table 14).\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tWT parent\t1\t0.3\t0.6\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tBC\tS25A\t1\t0.82\t2.9\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tBC\tL26A\t1\t2.3\t16\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tBC\tP27A\t1\t1.0\t10\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tBC\tH28A\t1\t0.86\t6.2\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tBC\tQ29A\t1\t0.71\t1.5\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tBC\tG30A\t2\t5\t14.0\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tBC\tK31A\t1\t0.62\t2.2\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tBC\tN33A\t1\t2.09\t9.8\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tDE\tG55A\t2\t>100\t>100\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tDE\tR56A\t1\t55\t>100\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tDE\tG57A\t1\t>100\t>100\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tDE\tV58A\t2\t1.63\t3.3\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tFG\tV80A\t1\t14.0\t>100\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tFG\tT81A\t1\t4.93\t2.0\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tFG\tD82A\t1\t0.81\t1.8\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tFG\tT83A\t1\t1.31\t1.8\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tFG\tG84A\t1\t2.03\t3.6\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tFG\tY85A\t1\t2.05\t5.5\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tFG\tL86A\t2\t1.41\t2.0\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tFG\tK87A\t1\t0.82\t2.0\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tFG\tY88A\t1\t11\t>100\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tFG\tK89A\t1\t0.71\t1.6"
    },
    {
        "molecule_name": "Q29A",
        "protein_target_name": "myostatin",
        "binding_metric": "IC50",
        "value": "1.5",
        "unit": "nM",
        "is_logarithmic": false,
        "raw_mentions": "Here are the extracted sentences/rows that meet the criteria:\n\n\nThe global Kd analysis shown in Table 13 gives a Kd of 170 pM with a 95% confidence interval of 330-60 pM.\nThese analyses indicate that PRD-1177 binds myostatin with a global Kd value of 250 pM and a 95% confidence interval of 340-130 pM (Table 13).\nATI-1338 binds myostatin with a global Kd value of 850 pM and a 95% confidence interval of 1400-330 pM.\nTABLE 13: Adnectin\tKd\tKd high\tKd low\tPRD-1474\t170 pM\t330 pM\t60 pM\nTABLE 13: Adnectin\tKd\tKd high\tKd low\tPRD-1177\t250 pM\t340 pM\t130 pM\nTABLE 13: Adnectin\tKd\tKd high\tKd low\tATI-1338\t850 pM\t1400 pM\t330 pM\nIn the HTRF competition binding assay, potencies ranged from IC50=1.5 nM to >100 nM (Table 14).\nMost positions tolerated alanine substitution in the HTRF assay to some degree, with the exception of Gly55, Arg56, and Gly57 of the DE loop, for which binding was drastically reduced (IC50s>100 nM).\nA lesser effect occurred in positions Gly30 of the BC loop, and Val80, Thr81, and Tyr88 of the FG loop, which still showed binding but with a >10-fold increase in IC50 relative to the parental sequence (“WT”).\nIn the ARE-luciferase cell-based assay, potency of mutants ranged from IC50=0.6 nM to >100 nM (Table 14).\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tWT parent\t1\t0.3\t0.6\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tBC\tS25A\t1\t0.82\t2.9\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tBC\tL26A\t1\t2.3\t16\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tBC\tP27A\t1\t1.0\t10\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tBC\tH28A\t1\t0.86\t6.2\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tBC\tQ29A\t1\t0.71\t1.5\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tBC\tG30A\t2\t5\t14.0\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tBC\tK31A\t1\t0.62\t2.2\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tBC\tN33A\t1\t2.09\t9.8\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tDE\tG55A\t2\t>100\t>100\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tDE\tR56A\t1\t55\t>100\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tDE\tG57A\t1\t>100\t>100\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tDE\tV58A\t2\t1.63\t3.3\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tFG\tV80A\t1\t14.0\t>100\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tFG\tT81A\t1\t4.93\t2.0\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tFG\tD82A\t1\t0.81\t1.8\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tFG\tT83A\t1\t1.31\t1.8\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tFG\tG84A\t1\t2.03\t3.6\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tFG\tY85A\t1\t2.05\t5.5\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tFG\tL86A\t2\t1.41\t2.0\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tFG\tK87A\t1\t0.82\t2.0\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tFG\tY88A\t1\t11\t>100\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tFG\tK89A\t1\t0.71\t1.6"
    },
    {
        "molecule_name": "G30A",
        "protein_target_name": "myostatin",
        "binding_metric": "IC50",
        "value": "5",
        "unit": "nM",
        "is_logarithmic": false,
        "raw_mentions": "Here are the extracted sentences/rows that meet the criteria:\n\n\nThe global Kd analysis shown in Table 13 gives a Kd of 170 pM with a 95% confidence interval of 330-60 pM.\nThese analyses indicate that PRD-1177 binds myostatin with a global Kd value of 250 pM and a 95% confidence interval of 340-130 pM (Table 13).\nATI-1338 binds myostatin with a global Kd value of 850 pM and a 95% confidence interval of 1400-330 pM.\nTABLE 13: Adnectin\tKd\tKd high\tKd low\tPRD-1474\t170 pM\t330 pM\t60 pM\nTABLE 13: Adnectin\tKd\tKd high\tKd low\tPRD-1177\t250 pM\t340 pM\t130 pM\nTABLE 13: Adnectin\tKd\tKd high\tKd low\tATI-1338\t850 pM\t1400 pM\t330 pM\nIn the HTRF competition binding assay, potencies ranged from IC50=1.5 nM to >100 nM (Table 14).\nMost positions tolerated alanine substitution in the HTRF assay to some degree, with the exception of Gly55, Arg56, and Gly57 of the DE loop, for which binding was drastically reduced (IC50s>100 nM).\nA lesser effect occurred in positions Gly30 of the BC loop, and Val80, Thr81, and Tyr88 of the FG loop, which still showed binding but with a >10-fold increase in IC50 relative to the parental sequence (“WT”).\nIn the ARE-luciferase cell-based assay, potency of mutants ranged from IC50=0.6 nM to >100 nM (Table 14).\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tWT parent\t1\t0.3\t0.6\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tBC\tS25A\t1\t0.82\t2.9\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tBC\tL26A\t1\t2.3\t16\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tBC\tP27A\t1\t1.0\t10\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tBC\tH28A\t1\t0.86\t6.2\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tBC\tQ29A\t1\t0.71\t1.5\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tBC\tG30A\t2\t5\t14.0\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tBC\tK31A\t1\t0.62\t2.2\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tBC\tN33A\t1\t2.09\t9.8\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tDE\tG55A\t2\t>100\t>100\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tDE\tR56A\t1\t55\t>100\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tDE\tG57A\t1\t>100\t>100\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tDE\tV58A\t2\t1.63\t3.3\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tFG\tV80A\t1\t14.0\t>100\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tFG\tT81A\t1\t4.93\t2.0\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tFG\tD82A\t1\t0.81\t1.8\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tFG\tT83A\t1\t1.31\t1.8\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tFG\tG84A\t1\t2.03\t3.6\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tFG\tY85A\t1\t2.05\t5.5\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tFG\tL86A\t2\t1.41\t2.0\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tFG\tK87A\t1\t0.82\t2.0\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tFG\tY88A\t1\t11\t>100\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tFG\tK89A\t1\t0.71\t1.6"
    },
    {
        "molecule_name": "G30A",
        "protein_target_name": "myostatin",
        "binding_metric": "IC50",
        "value": "14.0",
        "unit": "nM",
        "is_logarithmic": false,
        "raw_mentions": "Here are the extracted sentences/rows that meet the criteria:\n\n\nThe global Kd analysis shown in Table 13 gives a Kd of 170 pM with a 95% confidence interval of 330-60 pM.\nThese analyses indicate that PRD-1177 binds myostatin with a global Kd value of 250 pM and a 95% confidence interval of 340-130 pM (Table 13).\nATI-1338 binds myostatin with a global Kd value of 850 pM and a 95% confidence interval of 1400-330 pM.\nTABLE 13: Adnectin\tKd\tKd high\tKd low\tPRD-1474\t170 pM\t330 pM\t60 pM\nTABLE 13: Adnectin\tKd\tKd high\tKd low\tPRD-1177\t250 pM\t340 pM\t130 pM\nTABLE 13: Adnectin\tKd\tKd high\tKd low\tATI-1338\t850 pM\t1400 pM\t330 pM\nIn the HTRF competition binding assay, potencies ranged from IC50=1.5 nM to >100 nM (Table 14).\nMost positions tolerated alanine substitution in the HTRF assay to some degree, with the exception of Gly55, Arg56, and Gly57 of the DE loop, for which binding was drastically reduced (IC50s>100 nM).\nA lesser effect occurred in positions Gly30 of the BC loop, and Val80, Thr81, and Tyr88 of the FG loop, which still showed binding but with a >10-fold increase in IC50 relative to the parental sequence (“WT”).\nIn the ARE-luciferase cell-based assay, potency of mutants ranged from IC50=0.6 nM to >100 nM (Table 14).\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tWT parent\t1\t0.3\t0.6\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tBC\tS25A\t1\t0.82\t2.9\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tBC\tL26A\t1\t2.3\t16\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tBC\tP27A\t1\t1.0\t10\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tBC\tH28A\t1\t0.86\t6.2\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tBC\tQ29A\t1\t0.71\t1.5\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tBC\tG30A\t2\t5\t14.0\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tBC\tK31A\t1\t0.62\t2.2\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tBC\tN33A\t1\t2.09\t9.8\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tDE\tG55A\t2\t>100\t>100\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tDE\tR56A\t1\t55\t>100\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tDE\tG57A\t1\t>100\t>100\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tDE\tV58A\t2\t1.63\t3.3\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tFG\tV80A\t1\t14.0\t>100\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tFG\tT81A\t1\t4.93\t2.0\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tFG\tD82A\t1\t0.81\t1.8\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tFG\tT83A\t1\t1.31\t1.8\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tFG\tG84A\t1\t2.03\t3.6\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tFG\tY85A\t1\t2.05\t5.5\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tFG\tL86A\t2\t1.41\t2.0\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tFG\tK87A\t1\t0.82\t2.0\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tFG\tY88A\t1\t11\t>100\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tFG\tK89A\t1\t0.71\t1.6"
    },
    {
        "molecule_name": "K31A",
        "protein_target_name": "myostatin",
        "binding_metric": "IC50",
        "value": "0.62",
        "unit": "nM",
        "is_logarithmic": false,
        "raw_mentions": "Here are the extracted sentences/rows that meet the criteria:\n\n\nThe global Kd analysis shown in Table 13 gives a Kd of 170 pM with a 95% confidence interval of 330-60 pM.\nThese analyses indicate that PRD-1177 binds myostatin with a global Kd value of 250 pM and a 95% confidence interval of 340-130 pM (Table 13).\nATI-1338 binds myostatin with a global Kd value of 850 pM and a 95% confidence interval of 1400-330 pM.\nTABLE 13: Adnectin\tKd\tKd high\tKd low\tPRD-1474\t170 pM\t330 pM\t60 pM\nTABLE 13: Adnectin\tKd\tKd high\tKd low\tPRD-1177\t250 pM\t340 pM\t130 pM\nTABLE 13: Adnectin\tKd\tKd high\tKd low\tATI-1338\t850 pM\t1400 pM\t330 pM\nIn the HTRF competition binding assay, potencies ranged from IC50=1.5 nM to >100 nM (Table 14).\nMost positions tolerated alanine substitution in the HTRF assay to some degree, with the exception of Gly55, Arg56, and Gly57 of the DE loop, for which binding was drastically reduced (IC50s>100 nM).\nA lesser effect occurred in positions Gly30 of the BC loop, and Val80, Thr81, and Tyr88 of the FG loop, which still showed binding but with a >10-fold increase in IC50 relative to the parental sequence (“WT”).\nIn the ARE-luciferase cell-based assay, potency of mutants ranged from IC50=0.6 nM to >100 nM (Table 14).\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tWT parent\t1\t0.3\t0.6\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tBC\tS25A\t1\t0.82\t2.9\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tBC\tL26A\t1\t2.3\t16\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tBC\tP27A\t1\t1.0\t10\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tBC\tH28A\t1\t0.86\t6.2\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tBC\tQ29A\t1\t0.71\t1.5\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tBC\tG30A\t2\t5\t14.0\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tBC\tK31A\t1\t0.62\t2.2\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tBC\tN33A\t1\t2.09\t9.8\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tDE\tG55A\t2\t>100\t>100\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tDE\tR56A\t1\t55\t>100\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tDE\tG57A\t1\t>100\t>100\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tDE\tV58A\t2\t1.63\t3.3\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tFG\tV80A\t1\t14.0\t>100\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tFG\tT81A\t1\t4.93\t2.0\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tFG\tD82A\t1\t0.81\t1.8\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tFG\tT83A\t1\t1.31\t1.8\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tFG\tG84A\t1\t2.03\t3.6\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tFG\tY85A\t1\t2.05\t5.5\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tFG\tL86A\t2\t1.41\t2.0\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tFG\tK87A\t1\t0.82\t2.0\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tFG\tY88A\t1\t11\t>100\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tFG\tK89A\t1\t0.71\t1.6"
    },
    {
        "molecule_name": "K31A",
        "protein_target_name": "myostatin",
        "binding_metric": "IC50",
        "value": "2.2",
        "unit": "nM",
        "is_logarithmic": false,
        "raw_mentions": "Here are the extracted sentences/rows that meet the criteria:\n\n\nThe global Kd analysis shown in Table 13 gives a Kd of 170 pM with a 95% confidence interval of 330-60 pM.\nThese analyses indicate that PRD-1177 binds myostatin with a global Kd value of 250 pM and a 95% confidence interval of 340-130 pM (Table 13).\nATI-1338 binds myostatin with a global Kd value of 850 pM and a 95% confidence interval of 1400-330 pM.\nTABLE 13: Adnectin\tKd\tKd high\tKd low\tPRD-1474\t170 pM\t330 pM\t60 pM\nTABLE 13: Adnectin\tKd\tKd high\tKd low\tPRD-1177\t250 pM\t340 pM\t130 pM\nTABLE 13: Adnectin\tKd\tKd high\tKd low\tATI-1338\t850 pM\t1400 pM\t330 pM\nIn the HTRF competition binding assay, potencies ranged from IC50=1.5 nM to >100 nM (Table 14).\nMost positions tolerated alanine substitution in the HTRF assay to some degree, with the exception of Gly55, Arg56, and Gly57 of the DE loop, for which binding was drastically reduced (IC50s>100 nM).\nA lesser effect occurred in positions Gly30 of the BC loop, and Val80, Thr81, and Tyr88 of the FG loop, which still showed binding but with a >10-fold increase in IC50 relative to the parental sequence (“WT”).\nIn the ARE-luciferase cell-based assay, potency of mutants ranged from IC50=0.6 nM to >100 nM (Table 14).\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tWT parent\t1\t0.3\t0.6\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tBC\tS25A\t1\t0.82\t2.9\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tBC\tL26A\t1\t2.3\t16\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tBC\tP27A\t1\t1.0\t10\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tBC\tH28A\t1\t0.86\t6.2\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tBC\tQ29A\t1\t0.71\t1.5\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tBC\tG30A\t2\t5\t14.0\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tBC\tK31A\t1\t0.62\t2.2\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tBC\tN33A\t1\t2.09\t9.8\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tDE\tG55A\t2\t>100\t>100\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tDE\tR56A\t1\t55\t>100\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tDE\tG57A\t1\t>100\t>100\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tDE\tV58A\t2\t1.63\t3.3\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tFG\tV80A\t1\t14.0\t>100\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tFG\tT81A\t1\t4.93\t2.0\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tFG\tD82A\t1\t0.81\t1.8\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tFG\tT83A\t1\t1.31\t1.8\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tFG\tG84A\t1\t2.03\t3.6\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tFG\tY85A\t1\t2.05\t5.5\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tFG\tL86A\t2\t1.41\t2.0\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tFG\tK87A\t1\t0.82\t2.0\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tFG\tY88A\t1\t11\t>100\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tFG\tK89A\t1\t0.71\t1.6"
    },
    {
        "molecule_name": "N33A",
        "protein_target_name": "myostatin",
        "binding_metric": "IC50",
        "value": "2.09",
        "unit": "nM",
        "is_logarithmic": false,
        "raw_mentions": "Here are the extracted sentences/rows that meet the criteria:\n\n\nThe global Kd analysis shown in Table 13 gives a Kd of 170 pM with a 95% confidence interval of 330-60 pM.\nThese analyses indicate that PRD-1177 binds myostatin with a global Kd value of 250 pM and a 95% confidence interval of 340-130 pM (Table 13).\nATI-1338 binds myostatin with a global Kd value of 850 pM and a 95% confidence interval of 1400-330 pM.\nTABLE 13: Adnectin\tKd\tKd high\tKd low\tPRD-1474\t170 pM\t330 pM\t60 pM\nTABLE 13: Adnectin\tKd\tKd high\tKd low\tPRD-1177\t250 pM\t340 pM\t130 pM\nTABLE 13: Adnectin\tKd\tKd high\tKd low\tATI-1338\t850 pM\t1400 pM\t330 pM\nIn the HTRF competition binding assay, potencies ranged from IC50=1.5 nM to >100 nM (Table 14).\nMost positions tolerated alanine substitution in the HTRF assay to some degree, with the exception of Gly55, Arg56, and Gly57 of the DE loop, for which binding was drastically reduced (IC50s>100 nM).\nA lesser effect occurred in positions Gly30 of the BC loop, and Val80, Thr81, and Tyr88 of the FG loop, which still showed binding but with a >10-fold increase in IC50 relative to the parental sequence (“WT”).\nIn the ARE-luciferase cell-based assay, potency of mutants ranged from IC50=0.6 nM to >100 nM (Table 14).\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tWT parent\t1\t0.3\t0.6\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tBC\tS25A\t1\t0.82\t2.9\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tBC\tL26A\t1\t2.3\t16\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tBC\tP27A\t1\t1.0\t10\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tBC\tH28A\t1\t0.86\t6.2\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tBC\tQ29A\t1\t0.71\t1.5\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tBC\tG30A\t2\t5\t14.0\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tBC\tK31A\t1\t0.62\t2.2\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tBC\tN33A\t1\t2.09\t9.8\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tDE\tG55A\t2\t>100\t>100\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tDE\tR56A\t1\t55\t>100\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tDE\tG57A\t1\t>100\t>100\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tDE\tV58A\t2\t1.63\t3.3\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tFG\tV80A\t1\t14.0\t>100\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tFG\tT81A\t1\t4.93\t2.0\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tFG\tD82A\t1\t0.81\t1.8\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tFG\tT83A\t1\t1.31\t1.8\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tFG\tG84A\t1\t2.03\t3.6\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tFG\tY85A\t1\t2.05\t5.5\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tFG\tL86A\t2\t1.41\t2.0\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tFG\tK87A\t1\t0.82\t2.0\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tFG\tY88A\t1\t11\t>100\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tFG\tK89A\t1\t0.71\t1.6"
    },
    {
        "molecule_name": "N33A",
        "protein_target_name": "myostatin",
        "binding_metric": "IC50",
        "value": "9.8",
        "unit": "nM",
        "is_logarithmic": false,
        "raw_mentions": "Here are the extracted sentences/rows that meet the criteria:\n\n\nThe global Kd analysis shown in Table 13 gives a Kd of 170 pM with a 95% confidence interval of 330-60 pM.\nThese analyses indicate that PRD-1177 binds myostatin with a global Kd value of 250 pM and a 95% confidence interval of 340-130 pM (Table 13).\nATI-1338 binds myostatin with a global Kd value of 850 pM and a 95% confidence interval of 1400-330 pM.\nTABLE 13: Adnectin\tKd\tKd high\tKd low\tPRD-1474\t170 pM\t330 pM\t60 pM\nTABLE 13: Adnectin\tKd\tKd high\tKd low\tPRD-1177\t250 pM\t340 pM\t130 pM\nTABLE 13: Adnectin\tKd\tKd high\tKd low\tATI-1338\t850 pM\t1400 pM\t330 pM\nIn the HTRF competition binding assay, potencies ranged from IC50=1.5 nM to >100 nM (Table 14).\nMost positions tolerated alanine substitution in the HTRF assay to some degree, with the exception of Gly55, Arg56, and Gly57 of the DE loop, for which binding was drastically reduced (IC50s>100 nM).\nA lesser effect occurred in positions Gly30 of the BC loop, and Val80, Thr81, and Tyr88 of the FG loop, which still showed binding but with a >10-fold increase in IC50 relative to the parental sequence (“WT”).\nIn the ARE-luciferase cell-based assay, potency of mutants ranged from IC50=0.6 nM to >100 nM (Table 14).\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tWT parent\t1\t0.3\t0.6\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tBC\tS25A\t1\t0.82\t2.9\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tBC\tL26A\t1\t2.3\t16\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tBC\tP27A\t1\t1.0\t10\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tBC\tH28A\t1\t0.86\t6.2\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tBC\tQ29A\t1\t0.71\t1.5\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tBC\tG30A\t2\t5\t14.0\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tBC\tK31A\t1\t0.62\t2.2\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tBC\tN33A\t1\t2.09\t9.8\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tDE\tG55A\t2\t>100\t>100\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tDE\tR56A\t1\t55\t>100\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tDE\tG57A\t1\t>100\t>100\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tDE\tV58A\t2\t1.63\t3.3\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tFG\tV80A\t1\t14.0\t>100\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tFG\tT81A\t1\t4.93\t2.0\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tFG\tD82A\t1\t0.81\t1.8\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tFG\tT83A\t1\t1.31\t1.8\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tFG\tG84A\t1\t2.03\t3.6\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tFG\tY85A\t1\t2.05\t5.5\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tFG\tL86A\t2\t1.41\t2.0\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tFG\tK87A\t1\t0.82\t2.0\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tFG\tY88A\t1\t11\t>100\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tFG\tK89A\t1\t0.71\t1.6"
    },
    {
        "molecule_name": "G55A",
        "protein_target_name": "myostatin",
        "binding_metric": "IC50",
        "value": ">100",
        "unit": "nM",
        "is_logarithmic": false,
        "raw_mentions": "Here are the extracted sentences/rows that meet the criteria:\n\n\nThe global Kd analysis shown in Table 13 gives a Kd of 170 pM with a 95% confidence interval of 330-60 pM.\nThese analyses indicate that PRD-1177 binds myostatin with a global Kd value of 250 pM and a 95% confidence interval of 340-130 pM (Table 13).\nATI-1338 binds myostatin with a global Kd value of 850 pM and a 95% confidence interval of 1400-330 pM.\nTABLE 13: Adnectin\tKd\tKd high\tKd low\tPRD-1474\t170 pM\t330 pM\t60 pM\nTABLE 13: Adnectin\tKd\tKd high\tKd low\tPRD-1177\t250 pM\t340 pM\t130 pM\nTABLE 13: Adnectin\tKd\tKd high\tKd low\tATI-1338\t850 pM\t1400 pM\t330 pM\nIn the HTRF competition binding assay, potencies ranged from IC50=1.5 nM to >100 nM (Table 14).\nMost positions tolerated alanine substitution in the HTRF assay to some degree, with the exception of Gly55, Arg56, and Gly57 of the DE loop, for which binding was drastically reduced (IC50s>100 nM).\nA lesser effect occurred in positions Gly30 of the BC loop, and Val80, Thr81, and Tyr88 of the FG loop, which still showed binding but with a >10-fold increase in IC50 relative to the parental sequence (“WT”).\nIn the ARE-luciferase cell-based assay, potency of mutants ranged from IC50=0.6 nM to >100 nM (Table 14).\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tWT parent\t1\t0.3\t0.6\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tBC\tS25A\t1\t0.82\t2.9\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tBC\tL26A\t1\t2.3\t16\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tBC\tP27A\t1\t1.0\t10\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tBC\tH28A\t1\t0.86\t6.2\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tBC\tQ29A\t1\t0.71\t1.5\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tBC\tG30A\t2\t5\t14.0\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tBC\tK31A\t1\t0.62\t2.2\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tBC\tN33A\t1\t2.09\t9.8\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tDE\tG55A\t2\t>100\t>100\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tDE\tR56A\t1\t55\t>100\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tDE\tG57A\t1\t>100\t>100\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tDE\tV58A\t2\t1.63\t3.3\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tFG\tV80A\t1\t14.0\t>100\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tFG\tT81A\t1\t4.93\t2.0\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tFG\tD82A\t1\t0.81\t1.8\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tFG\tT83A\t1\t1.31\t1.8\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tFG\tG84A\t1\t2.03\t3.6\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tFG\tY85A\t1\t2.05\t5.5\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tFG\tL86A\t2\t1.41\t2.0\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tFG\tK87A\t1\t0.82\t2.0\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tFG\tY88A\t1\t11\t>100\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tFG\tK89A\t1\t0.71\t1.6"
    },
    {
        "molecule_name": "G55A",
        "protein_target_name": "myostatin",
        "binding_metric": "IC50",
        "value": ">100",
        "unit": "nM",
        "is_logarithmic": false,
        "raw_mentions": "Here are the extracted sentences/rows that meet the criteria:\n\n\nThe global Kd analysis shown in Table 13 gives a Kd of 170 pM with a 95% confidence interval of 330-60 pM.\nThese analyses indicate that PRD-1177 binds myostatin with a global Kd value of 250 pM and a 95% confidence interval of 340-130 pM (Table 13).\nATI-1338 binds myostatin with a global Kd value of 850 pM and a 95% confidence interval of 1400-330 pM.\nTABLE 13: Adnectin\tKd\tKd high\tKd low\tPRD-1474\t170 pM\t330 pM\t60 pM\nTABLE 13: Adnectin\tKd\tKd high\tKd low\tPRD-1177\t250 pM\t340 pM\t130 pM\nTABLE 13: Adnectin\tKd\tKd high\tKd low\tATI-1338\t850 pM\t1400 pM\t330 pM\nIn the HTRF competition binding assay, potencies ranged from IC50=1.5 nM to >100 nM (Table 14).\nMost positions tolerated alanine substitution in the HTRF assay to some degree, with the exception of Gly55, Arg56, and Gly57 of the DE loop, for which binding was drastically reduced (IC50s>100 nM).\nA lesser effect occurred in positions Gly30 of the BC loop, and Val80, Thr81, and Tyr88 of the FG loop, which still showed binding but with a >10-fold increase in IC50 relative to the parental sequence (“WT”).\nIn the ARE-luciferase cell-based assay, potency of mutants ranged from IC50=0.6 nM to >100 nM (Table 14).\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tWT parent\t1\t0.3\t0.6\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tBC\tS25A\t1\t0.82\t2.9\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tBC\tL26A\t1\t2.3\t16\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tBC\tP27A\t1\t1.0\t10\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tBC\tH28A\t1\t0.86\t6.2\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tBC\tQ29A\t1\t0.71\t1.5\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tBC\tG30A\t2\t5\t14.0\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tBC\tK31A\t1\t0.62\t2.2\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tBC\tN33A\t1\t2.09\t9.8\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tDE\tG55A\t2\t>100\t>100\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tDE\tR56A\t1\t55\t>100\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tDE\tG57A\t1\t>100\t>100\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tDE\tV58A\t2\t1.63\t3.3\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tFG\tV80A\t1\t14.0\t>100\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tFG\tT81A\t1\t4.93\t2.0\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tFG\tD82A\t1\t0.81\t1.8\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tFG\tT83A\t1\t1.31\t1.8\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tFG\tG84A\t1\t2.03\t3.6\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tFG\tY85A\t1\t2.05\t5.5\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tFG\tL86A\t2\t1.41\t2.0\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tFG\tK87A\t1\t0.82\t2.0\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tFG\tY88A\t1\t11\t>100\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tFG\tK89A\t1\t0.71\t1.6"
    },
    {
        "molecule_name": "R56A",
        "protein_target_name": "myostatin",
        "binding_metric": "IC50",
        "value": "55",
        "unit": "nM",
        "is_logarithmic": false,
        "raw_mentions": "Here are the extracted sentences/rows that meet the criteria:\n\n\nThe global Kd analysis shown in Table 13 gives a Kd of 170 pM with a 95% confidence interval of 330-60 pM.\nThese analyses indicate that PRD-1177 binds myostatin with a global Kd value of 250 pM and a 95% confidence interval of 340-130 pM (Table 13).\nATI-1338 binds myostatin with a global Kd value of 850 pM and a 95% confidence interval of 1400-330 pM.\nTABLE 13: Adnectin\tKd\tKd high\tKd low\tPRD-1474\t170 pM\t330 pM\t60 pM\nTABLE 13: Adnectin\tKd\tKd high\tKd low\tPRD-1177\t250 pM\t340 pM\t130 pM\nTABLE 13: Adnectin\tKd\tKd high\tKd low\tATI-1338\t850 pM\t1400 pM\t330 pM\nIn the HTRF competition binding assay, potencies ranged from IC50=1.5 nM to >100 nM (Table 14).\nMost positions tolerated alanine substitution in the HTRF assay to some degree, with the exception of Gly55, Arg56, and Gly57 of the DE loop, for which binding was drastically reduced (IC50s>100 nM).\nA lesser effect occurred in positions Gly30 of the BC loop, and Val80, Thr81, and Tyr88 of the FG loop, which still showed binding but with a >10-fold increase in IC50 relative to the parental sequence (“WT”).\nIn the ARE-luciferase cell-based assay, potency of mutants ranged from IC50=0.6 nM to >100 nM (Table 14).\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tWT parent\t1\t0.3\t0.6\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tBC\tS25A\t1\t0.82\t2.9\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tBC\tL26A\t1\t2.3\t16\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tBC\tP27A\t1\t1.0\t10\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tBC\tH28A\t1\t0.86\t6.2\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tBC\tQ29A\t1\t0.71\t1.5\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tBC\tG30A\t2\t5\t14.0\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tBC\tK31A\t1\t0.62\t2.2\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tBC\tN33A\t1\t2.09\t9.8\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tDE\tG55A\t2\t>100\t>100\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tDE\tR56A\t1\t55\t>100\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tDE\tG57A\t1\t>100\t>100\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tDE\tV58A\t2\t1.63\t3.3\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tFG\tV80A\t1\t14.0\t>100\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tFG\tT81A\t1\t4.93\t2.0\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tFG\tD82A\t1\t0.81\t1.8\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tFG\tT83A\t1\t1.31\t1.8\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tFG\tG84A\t1\t2.03\t3.6\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tFG\tY85A\t1\t2.05\t5.5\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tFG\tL86A\t2\t1.41\t2.0\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tFG\tK87A\t1\t0.82\t2.0\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tFG\tY88A\t1\t11\t>100\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tFG\tK89A\t1\t0.71\t1.6"
    },
    {
        "molecule_name": "R56A",
        "protein_target_name": "myostatin",
        "binding_metric": "IC50",
        "value": ">100",
        "unit": "nM",
        "is_logarithmic": false,
        "raw_mentions": "Here are the extracted sentences/rows that meet the criteria:\n\n\nThe global Kd analysis shown in Table 13 gives a Kd of 170 pM with a 95% confidence interval of 330-60 pM.\nThese analyses indicate that PRD-1177 binds myostatin with a global Kd value of 250 pM and a 95% confidence interval of 340-130 pM (Table 13).\nATI-1338 binds myostatin with a global Kd value of 850 pM and a 95% confidence interval of 1400-330 pM.\nTABLE 13: Adnectin\tKd\tKd high\tKd low\tPRD-1474\t170 pM\t330 pM\t60 pM\nTABLE 13: Adnectin\tKd\tKd high\tKd low\tPRD-1177\t250 pM\t340 pM\t130 pM\nTABLE 13: Adnectin\tKd\tKd high\tKd low\tATI-1338\t850 pM\t1400 pM\t330 pM\nIn the HTRF competition binding assay, potencies ranged from IC50=1.5 nM to >100 nM (Table 14).\nMost positions tolerated alanine substitution in the HTRF assay to some degree, with the exception of Gly55, Arg56, and Gly57 of the DE loop, for which binding was drastically reduced (IC50s>100 nM).\nA lesser effect occurred in positions Gly30 of the BC loop, and Val80, Thr81, and Tyr88 of the FG loop, which still showed binding but with a >10-fold increase in IC50 relative to the parental sequence (“WT”).\nIn the ARE-luciferase cell-based assay, potency of mutants ranged from IC50=0.6 nM to >100 nM (Table 14).\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tWT parent\t1\t0.3\t0.6\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tBC\tS25A\t1\t0.82\t2.9\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tBC\tL26A\t1\t2.3\t16\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tBC\tP27A\t1\t1.0\t10\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tBC\tH28A\t1\t0.86\t6.2\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tBC\tQ29A\t1\t0.71\t1.5\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tBC\tG30A\t2\t5\t14.0\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tBC\tK31A\t1\t0.62\t2.2\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tBC\tN33A\t1\t2.09\t9.8\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tDE\tG55A\t2\t>100\t>100\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tDE\tR56A\t1\t55\t>100\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tDE\tG57A\t1\t>100\t>100\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tDE\tV58A\t2\t1.63\t3.3\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tFG\tV80A\t1\t14.0\t>100\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tFG\tT81A\t1\t4.93\t2.0\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tFG\tD82A\t1\t0.81\t1.8\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tFG\tT83A\t1\t1.31\t1.8\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tFG\tG84A\t1\t2.03\t3.6\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tFG\tY85A\t1\t2.05\t5.5\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tFG\tL86A\t2\t1.41\t2.0\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tFG\tK87A\t1\t0.82\t2.0\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tFG\tY88A\t1\t11\t>100\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tFG\tK89A\t1\t0.71\t1.6"
    },
    {
        "molecule_name": "G57A",
        "protein_target_name": "myostatin",
        "binding_metric": "IC50",
        "value": ">100",
        "unit": "nM",
        "is_logarithmic": false,
        "raw_mentions": "Here are the extracted sentences/rows that meet the criteria:\n\n\nThe global Kd analysis shown in Table 13 gives a Kd of 170 pM with a 95% confidence interval of 330-60 pM.\nThese analyses indicate that PRD-1177 binds myostatin with a global Kd value of 250 pM and a 95% confidence interval of 340-130 pM (Table 13).\nATI-1338 binds myostatin with a global Kd value of 850 pM and a 95% confidence interval of 1400-330 pM.\nTABLE 13: Adnectin\tKd\tKd high\tKd low\tPRD-1474\t170 pM\t330 pM\t60 pM\nTABLE 13: Adnectin\tKd\tKd high\tKd low\tPRD-1177\t250 pM\t340 pM\t130 pM\nTABLE 13: Adnectin\tKd\tKd high\tKd low\tATI-1338\t850 pM\t1400 pM\t330 pM\nIn the HTRF competition binding assay, potencies ranged from IC50=1.5 nM to >100 nM (Table 14).\nMost positions tolerated alanine substitution in the HTRF assay to some degree, with the exception of Gly55, Arg56, and Gly57 of the DE loop, for which binding was drastically reduced (IC50s>100 nM).\nA lesser effect occurred in positions Gly30 of the BC loop, and Val80, Thr81, and Tyr88 of the FG loop, which still showed binding but with a >10-fold increase in IC50 relative to the parental sequence (“WT”).\nIn the ARE-luciferase cell-based assay, potency of mutants ranged from IC50=0.6 nM to >100 nM (Table 14).\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tWT parent\t1\t0.3\t0.6\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tBC\tS25A\t1\t0.82\t2.9\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tBC\tL26A\t1\t2.3\t16\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tBC\tP27A\t1\t1.0\t10\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tBC\tH28A\t1\t0.86\t6.2\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tBC\tQ29A\t1\t0.71\t1.5\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tBC\tG30A\t2\t5\t14.0\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tBC\tK31A\t1\t0.62\t2.2\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tBC\tN33A\t1\t2.09\t9.8\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tDE\tG55A\t2\t>100\t>100\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tDE\tR56A\t1\t55\t>100\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tDE\tG57A\t1\t>100\t>100\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tDE\tV58A\t2\t1.63\t3.3\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tFG\tV80A\t1\t14.0\t>100\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tFG\tT81A\t1\t4.93\t2.0\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tFG\tD82A\t1\t0.81\t1.8\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tFG\tT83A\t1\t1.31\t1.8\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tFG\tG84A\t1\t2.03\t3.6\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tFG\tY85A\t1\t2.05\t5.5\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tFG\tL86A\t2\t1.41\t2.0\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tFG\tK87A\t1\t0.82\t2.0\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tFG\tY88A\t1\t11\t>100\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tFG\tK89A\t1\t0.71\t1.6"
    },
    {
        "molecule_name": "G57A",
        "protein_target_name": "myostatin",
        "binding_metric": "IC50",
        "value": ">100",
        "unit": "nM",
        "is_logarithmic": false,
        "raw_mentions": "Here are the extracted sentences/rows that meet the criteria:\n\n\nThe global Kd analysis shown in Table 13 gives a Kd of 170 pM with a 95% confidence interval of 330-60 pM.\nThese analyses indicate that PRD-1177 binds myostatin with a global Kd value of 250 pM and a 95% confidence interval of 340-130 pM (Table 13).\nATI-1338 binds myostatin with a global Kd value of 850 pM and a 95% confidence interval of 1400-330 pM.\nTABLE 13: Adnectin\tKd\tKd high\tKd low\tPRD-1474\t170 pM\t330 pM\t60 pM\nTABLE 13: Adnectin\tKd\tKd high\tKd low\tPRD-1177\t250 pM\t340 pM\t130 pM\nTABLE 13: Adnectin\tKd\tKd high\tKd low\tATI-1338\t850 pM\t1400 pM\t330 pM\nIn the HTRF competition binding assay, potencies ranged from IC50=1.5 nM to >100 nM (Table 14).\nMost positions tolerated alanine substitution in the HTRF assay to some degree, with the exception of Gly55, Arg56, and Gly57 of the DE loop, for which binding was drastically reduced (IC50s>100 nM).\nA lesser effect occurred in positions Gly30 of the BC loop, and Val80, Thr81, and Tyr88 of the FG loop, which still showed binding but with a >10-fold increase in IC50 relative to the parental sequence (“WT”).\nIn the ARE-luciferase cell-based assay, potency of mutants ranged from IC50=0.6 nM to >100 nM (Table 14).\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tWT parent\t1\t0.3\t0.6\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tBC\tS25A\t1\t0.82\t2.9\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tBC\tL26A\t1\t2.3\t16\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tBC\tP27A\t1\t1.0\t10\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tBC\tH28A\t1\t0.86\t6.2\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tBC\tQ29A\t1\t0.71\t1.5\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tBC\tG30A\t2\t5\t14.0\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tBC\tK31A\t1\t0.62\t2.2\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tBC\tN33A\t1\t2.09\t9.8\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tDE\tG55A\t2\t>100\t>100\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tDE\tR56A\t1\t55\t>100\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tDE\tG57A\t1\t>100\t>100\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tDE\tV58A\t2\t1.63\t3.3\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tFG\tV80A\t1\t14.0\t>100\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tFG\tT81A\t1\t4.93\t2.0\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tFG\tD82A\t1\t0.81\t1.8\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tFG\tT83A\t1\t1.31\t1.8\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tFG\tG84A\t1\t2.03\t3.6\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tFG\tY85A\t1\t2.05\t5.5\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tFG\tL86A\t2\t1.41\t2.0\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tFG\tK87A\t1\t0.82\t2.0\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tFG\tY88A\t1\t11\t>100\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tFG\tK89A\t1\t0.71\t1.6"
    },
    {
        "molecule_name": "V58A",
        "protein_target_name": "myostatin",
        "binding_metric": "IC50",
        "value": "1.63",
        "unit": "nM",
        "is_logarithmic": false,
        "raw_mentions": "Here are the extracted sentences/rows that meet the criteria:\n\n\nThe global Kd analysis shown in Table 13 gives a Kd of 170 pM with a 95% confidence interval of 330-60 pM.\nThese analyses indicate that PRD-1177 binds myostatin with a global Kd value of 250 pM and a 95% confidence interval of 340-130 pM (Table 13).\nATI-1338 binds myostatin with a global Kd value of 850 pM and a 95% confidence interval of 1400-330 pM.\nTABLE 13: Adnectin\tKd\tKd high\tKd low\tPRD-1474\t170 pM\t330 pM\t60 pM\nTABLE 13: Adnectin\tKd\tKd high\tKd low\tPRD-1177\t250 pM\t340 pM\t130 pM\nTABLE 13: Adnectin\tKd\tKd high\tKd low\tATI-1338\t850 pM\t1400 pM\t330 pM\nIn the HTRF competition binding assay, potencies ranged from IC50=1.5 nM to >100 nM (Table 14).\nMost positions tolerated alanine substitution in the HTRF assay to some degree, with the exception of Gly55, Arg56, and Gly57 of the DE loop, for which binding was drastically reduced (IC50s>100 nM).\nA lesser effect occurred in positions Gly30 of the BC loop, and Val80, Thr81, and Tyr88 of the FG loop, which still showed binding but with a >10-fold increase in IC50 relative to the parental sequence (“WT”).\nIn the ARE-luciferase cell-based assay, potency of mutants ranged from IC50=0.6 nM to >100 nM (Table 14).\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tWT parent\t1\t0.3\t0.6\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tBC\tS25A\t1\t0.82\t2.9\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tBC\tL26A\t1\t2.3\t16\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tBC\tP27A\t1\t1.0\t10\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tBC\tH28A\t1\t0.86\t6.2\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tBC\tQ29A\t1\t0.71\t1.5\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tBC\tG30A\t2\t5\t14.0\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tBC\tK31A\t1\t0.62\t2.2\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tBC\tN33A\t1\t2.09\t9.8\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tDE\tG55A\t2\t>100\t>100\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tDE\tR56A\t1\t55\t>100\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tDE\tG57A\t1\t>100\t>100\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tDE\tV58A\t2\t1.63\t3.3\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tFG\tV80A\t1\t14.0\t>100\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tFG\tT81A\t1\t4.93\t2.0\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tFG\tD82A\t1\t0.81\t1.8\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tFG\tT83A\t1\t1.31\t1.8\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tFG\tG84A\t1\t2.03\t3.6\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tFG\tY85A\t1\t2.05\t5.5\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tFG\tL86A\t2\t1.41\t2.0\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tFG\tK87A\t1\t0.82\t2.0\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tFG\tY88A\t1\t11\t>100\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tFG\tK89A\t1\t0.71\t1.6"
    },
    {
        "molecule_name": "V58A",
        "protein_target_name": "myostatin",
        "binding_metric": "IC50",
        "value": "3.3",
        "unit": "nM",
        "is_logarithmic": false,
        "raw_mentions": "Here are the extracted sentences/rows that meet the criteria:\n\n\nThe global Kd analysis shown in Table 13 gives a Kd of 170 pM with a 95% confidence interval of 330-60 pM.\nThese analyses indicate that PRD-1177 binds myostatin with a global Kd value of 250 pM and a 95% confidence interval of 340-130 pM (Table 13).\nATI-1338 binds myostatin with a global Kd value of 850 pM and a 95% confidence interval of 1400-330 pM.\nTABLE 13: Adnectin\tKd\tKd high\tKd low\tPRD-1474\t170 pM\t330 pM\t60 pM\nTABLE 13: Adnectin\tKd\tKd high\tKd low\tPRD-1177\t250 pM\t340 pM\t130 pM\nTABLE 13: Adnectin\tKd\tKd high\tKd low\tATI-1338\t850 pM\t1400 pM\t330 pM\nIn the HTRF competition binding assay, potencies ranged from IC50=1.5 nM to >100 nM (Table 14).\nMost positions tolerated alanine substitution in the HTRF assay to some degree, with the exception of Gly55, Arg56, and Gly57 of the DE loop, for which binding was drastically reduced (IC50s>100 nM).\nA lesser effect occurred in positions Gly30 of the BC loop, and Val80, Thr81, and Tyr88 of the FG loop, which still showed binding but with a >10-fold increase in IC50 relative to the parental sequence (“WT”).\nIn the ARE-luciferase cell-based assay, potency of mutants ranged from IC50=0.6 nM to >100 nM (Table 14).\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tWT parent\t1\t0.3\t0.6\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tBC\tS25A\t1\t0.82\t2.9\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tBC\tL26A\t1\t2.3\t16\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tBC\tP27A\t1\t1.0\t10\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tBC\tH28A\t1\t0.86\t6.2\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tBC\tQ29A\t1\t0.71\t1.5\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tBC\tG30A\t2\t5\t14.0\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tBC\tK31A\t1\t0.62\t2.2\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tBC\tN33A\t1\t2.09\t9.8\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tDE\tG55A\t2\t>100\t>100\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tDE\tR56A\t1\t55\t>100\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tDE\tG57A\t1\t>100\t>100\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tDE\tV58A\t2\t1.63\t3.3\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tFG\tV80A\t1\t14.0\t>100\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tFG\tT81A\t1\t4.93\t2.0\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tFG\tD82A\t1\t0.81\t1.8\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tFG\tT83A\t1\t1.31\t1.8\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tFG\tG84A\t1\t2.03\t3.6\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tFG\tY85A\t1\t2.05\t5.5\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tFG\tL86A\t2\t1.41\t2.0\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tFG\tK87A\t1\t0.82\t2.0\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tFG\tY88A\t1\t11\t>100\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tFG\tK89A\t1\t0.71\t1.6"
    },
    {
        "molecule_name": "V80A",
        "protein_target_name": "myostatin",
        "binding_metric": "IC50",
        "value": "14.0",
        "unit": "nM",
        "is_logarithmic": false,
        "raw_mentions": "Here are the extracted sentences/rows that meet the criteria:\n\n\nThe global Kd analysis shown in Table 13 gives a Kd of 170 pM with a 95% confidence interval of 330-60 pM.\nThese analyses indicate that PRD-1177 binds myostatin with a global Kd value of 250 pM and a 95% confidence interval of 340-130 pM (Table 13).\nATI-1338 binds myostatin with a global Kd value of 850 pM and a 95% confidence interval of 1400-330 pM.\nTABLE 13: Adnectin\tKd\tKd high\tKd low\tPRD-1474\t170 pM\t330 pM\t60 pM\nTABLE 13: Adnectin\tKd\tKd high\tKd low\tPRD-1177\t250 pM\t340 pM\t130 pM\nTABLE 13: Adnectin\tKd\tKd high\tKd low\tATI-1338\t850 pM\t1400 pM\t330 pM\nIn the HTRF competition binding assay, potencies ranged from IC50=1.5 nM to >100 nM (Table 14).\nMost positions tolerated alanine substitution in the HTRF assay to some degree, with the exception of Gly55, Arg56, and Gly57 of the DE loop, for which binding was drastically reduced (IC50s>100 nM).\nA lesser effect occurred in positions Gly30 of the BC loop, and Val80, Thr81, and Tyr88 of the FG loop, which still showed binding but with a >10-fold increase in IC50 relative to the parental sequence (“WT”).\nIn the ARE-luciferase cell-based assay, potency of mutants ranged from IC50=0.6 nM to >100 nM (Table 14).\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tWT parent\t1\t0.3\t0.6\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tBC\tS25A\t1\t0.82\t2.9\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tBC\tL26A\t1\t2.3\t16\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tBC\tP27A\t1\t1.0\t10\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tBC\tH28A\t1\t0.86\t6.2\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tBC\tQ29A\t1\t0.71\t1.5\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tBC\tG30A\t2\t5\t14.0\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tBC\tK31A\t1\t0.62\t2.2\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tBC\tN33A\t1\t2.09\t9.8\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tDE\tG55A\t2\t>100\t>100\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tDE\tR56A\t1\t55\t>100\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tDE\tG57A\t1\t>100\t>100\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tDE\tV58A\t2\t1.63\t3.3\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tFG\tV80A\t1\t14.0\t>100\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tFG\tT81A\t1\t4.93\t2.0\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tFG\tD82A\t1\t0.81\t1.8\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tFG\tT83A\t1\t1.31\t1.8\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tFG\tG84A\t1\t2.03\t3.6\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tFG\tY85A\t1\t2.05\t5.5\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tFG\tL86A\t2\t1.41\t2.0\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tFG\tK87A\t1\t0.82\t2.0\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tFG\tY88A\t1\t11\t>100\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tFG\tK89A\t1\t0.71\t1.6"
    },
    {
        "molecule_name": "V80A",
        "protein_target_name": "myostatin",
        "binding_metric": "IC50",
        "value": ">100",
        "unit": "nM",
        "is_logarithmic": false,
        "raw_mentions": "Here are the extracted sentences/rows that meet the criteria:\n\n\nThe global Kd analysis shown in Table 13 gives a Kd of 170 pM with a 95% confidence interval of 330-60 pM.\nThese analyses indicate that PRD-1177 binds myostatin with a global Kd value of 250 pM and a 95% confidence interval of 340-130 pM (Table 13).\nATI-1338 binds myostatin with a global Kd value of 850 pM and a 95% confidence interval of 1400-330 pM.\nTABLE 13: Adnectin\tKd\tKd high\tKd low\tPRD-1474\t170 pM\t330 pM\t60 pM\nTABLE 13: Adnectin\tKd\tKd high\tKd low\tPRD-1177\t250 pM\t340 pM\t130 pM\nTABLE 13: Adnectin\tKd\tKd high\tKd low\tATI-1338\t850 pM\t1400 pM\t330 pM\nIn the HTRF competition binding assay, potencies ranged from IC50=1.5 nM to >100 nM (Table 14).\nMost positions tolerated alanine substitution in the HTRF assay to some degree, with the exception of Gly55, Arg56, and Gly57 of the DE loop, for which binding was drastically reduced (IC50s>100 nM).\nA lesser effect occurred in positions Gly30 of the BC loop, and Val80, Thr81, and Tyr88 of the FG loop, which still showed binding but with a >10-fold increase in IC50 relative to the parental sequence (“WT”).\nIn the ARE-luciferase cell-based assay, potency of mutants ranged from IC50=0.6 nM to >100 nM (Table 14).\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tWT parent\t1\t0.3\t0.6\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tBC\tS25A\t1\t0.82\t2.9\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tBC\tL26A\t1\t2.3\t16\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tBC\tP27A\t1\t1.0\t10\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tBC\tH28A\t1\t0.86\t6.2\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tBC\tQ29A\t1\t0.71\t1.5\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tBC\tG30A\t2\t5\t14.0\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tBC\tK31A\t1\t0.62\t2.2\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tBC\tN33A\t1\t2.09\t9.8\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tDE\tG55A\t2\t>100\t>100\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tDE\tR56A\t1\t55\t>100\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tDE\tG57A\t1\t>100\t>100\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tDE\tV58A\t2\t1.63\t3.3\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tFG\tV80A\t1\t14.0\t>100\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tFG\tT81A\t1\t4.93\t2.0\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tFG\tD82A\t1\t0.81\t1.8\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tFG\tT83A\t1\t1.31\t1.8\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tFG\tG84A\t1\t2.03\t3.6\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tFG\tY85A\t1\t2.05\t5.5\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tFG\tL86A\t2\t1.41\t2.0\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tFG\tK87A\t1\t0.82\t2.0\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tFG\tY88A\t1\t11\t>100\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tFG\tK89A\t1\t0.71\t1.6"
    },
    {
        "molecule_name": "T81A",
        "protein_target_name": "myostatin",
        "binding_metric": "IC50",
        "value": "4.93",
        "unit": "nM",
        "is_logarithmic": false,
        "raw_mentions": "Here are the extracted sentences/rows that meet the criteria:\n\n\nThe global Kd analysis shown in Table 13 gives a Kd of 170 pM with a 95% confidence interval of 330-60 pM.\nThese analyses indicate that PRD-1177 binds myostatin with a global Kd value of 250 pM and a 95% confidence interval of 340-130 pM (Table 13).\nATI-1338 binds myostatin with a global Kd value of 850 pM and a 95% confidence interval of 1400-330 pM.\nTABLE 13: Adnectin\tKd\tKd high\tKd low\tPRD-1474\t170 pM\t330 pM\t60 pM\nTABLE 13: Adnectin\tKd\tKd high\tKd low\tPRD-1177\t250 pM\t340 pM\t130 pM\nTABLE 13: Adnectin\tKd\tKd high\tKd low\tATI-1338\t850 pM\t1400 pM\t330 pM\nIn the HTRF competition binding assay, potencies ranged from IC50=1.5 nM to >100 nM (Table 14).\nMost positions tolerated alanine substitution in the HTRF assay to some degree, with the exception of Gly55, Arg56, and Gly57 of the DE loop, for which binding was drastically reduced (IC50s>100 nM).\nA lesser effect occurred in positions Gly30 of the BC loop, and Val80, Thr81, and Tyr88 of the FG loop, which still showed binding but with a >10-fold increase in IC50 relative to the parental sequence (“WT”).\nIn the ARE-luciferase cell-based assay, potency of mutants ranged from IC50=0.6 nM to >100 nM (Table 14).\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tWT parent\t1\t0.3\t0.6\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tBC\tS25A\t1\t0.82\t2.9\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tBC\tL26A\t1\t2.3\t16\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tBC\tP27A\t1\t1.0\t10\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tBC\tH28A\t1\t0.86\t6.2\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tBC\tQ29A\t1\t0.71\t1.5\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tBC\tG30A\t2\t5\t14.0\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tBC\tK31A\t1\t0.62\t2.2\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tBC\tN33A\t1\t2.09\t9.8\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tDE\tG55A\t2\t>100\t>100\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tDE\tR56A\t1\t55\t>100\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tDE\tG57A\t1\t>100\t>100\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tDE\tV58A\t2\t1.63\t3.3\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tFG\tV80A\t1\t14.0\t>100\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tFG\tT81A\t1\t4.93\t2.0\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tFG\tD82A\t1\t0.81\t1.8\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tFG\tT83A\t1\t1.31\t1.8\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tFG\tG84A\t1\t2.03\t3.6\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tFG\tY85A\t1\t2.05\t5.5\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tFG\tL86A\t2\t1.41\t2.0\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tFG\tK87A\t1\t0.82\t2.0\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tFG\tY88A\t1\t11\t>100\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tFG\tK89A\t1\t0.71\t1.6"
    },
    {
        "molecule_name": "T81A",
        "protein_target_name": "myostatin",
        "binding_metric": "IC50",
        "value": "2.0",
        "unit": "nM",
        "is_logarithmic": false,
        "raw_mentions": "Here are the extracted sentences/rows that meet the criteria:\n\n\nThe global Kd analysis shown in Table 13 gives a Kd of 170 pM with a 95% confidence interval of 330-60 pM.\nThese analyses indicate that PRD-1177 binds myostatin with a global Kd value of 250 pM and a 95% confidence interval of 340-130 pM (Table 13).\nATI-1338 binds myostatin with a global Kd value of 850 pM and a 95% confidence interval of 1400-330 pM.\nTABLE 13: Adnectin\tKd\tKd high\tKd low\tPRD-1474\t170 pM\t330 pM\t60 pM\nTABLE 13: Adnectin\tKd\tKd high\tKd low\tPRD-1177\t250 pM\t340 pM\t130 pM\nTABLE 13: Adnectin\tKd\tKd high\tKd low\tATI-1338\t850 pM\t1400 pM\t330 pM\nIn the HTRF competition binding assay, potencies ranged from IC50=1.5 nM to >100 nM (Table 14).\nMost positions tolerated alanine substitution in the HTRF assay to some degree, with the exception of Gly55, Arg56, and Gly57 of the DE loop, for which binding was drastically reduced (IC50s>100 nM).\nA lesser effect occurred in positions Gly30 of the BC loop, and Val80, Thr81, and Tyr88 of the FG loop, which still showed binding but with a >10-fold increase in IC50 relative to the parental sequence (“WT”).\nIn the ARE-luciferase cell-based assay, potency of mutants ranged from IC50=0.6 nM to >100 nM (Table 14).\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tWT parent\t1\t0.3\t0.6\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tBC\tS25A\t1\t0.82\t2.9\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tBC\tL26A\t1\t2.3\t16\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tBC\tP27A\t1\t1.0\t10\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tBC\tH28A\t1\t0.86\t6.2\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tBC\tQ29A\t1\t0.71\t1.5\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tBC\tG30A\t2\t5\t14.0\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tBC\tK31A\t1\t0.62\t2.2\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tBC\tN33A\t1\t2.09\t9.8\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tDE\tG55A\t2\t>100\t>100\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tDE\tR56A\t1\t55\t>100\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tDE\tG57A\t1\t>100\t>100\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tDE\tV58A\t2\t1.63\t3.3\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tFG\tV80A\t1\t14.0\t>100\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tFG\tT81A\t1\t4.93\t2.0\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tFG\tD82A\t1\t0.81\t1.8\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tFG\tT83A\t1\t1.31\t1.8\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tFG\tG84A\t1\t2.03\t3.6\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tFG\tY85A\t1\t2.05\t5.5\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tFG\tL86A\t2\t1.41\t2.0\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tFG\tK87A\t1\t0.82\t2.0\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tFG\tY88A\t1\t11\t>100\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tFG\tK89A\t1\t0.71\t1.6"
    },
    {
        "molecule_name": "D82A",
        "protein_target_name": "myostatin",
        "binding_metric": "IC50",
        "value": "0.81",
        "unit": "nM",
        "is_logarithmic": false,
        "raw_mentions": "Here are the extracted sentences/rows that meet the criteria:\n\n\nThe global Kd analysis shown in Table 13 gives a Kd of 170 pM with a 95% confidence interval of 330-60 pM.\nThese analyses indicate that PRD-1177 binds myostatin with a global Kd value of 250 pM and a 95% confidence interval of 340-130 pM (Table 13).\nATI-1338 binds myostatin with a global Kd value of 850 pM and a 95% confidence interval of 1400-330 pM.\nTABLE 13: Adnectin\tKd\tKd high\tKd low\tPRD-1474\t170 pM\t330 pM\t60 pM\nTABLE 13: Adnectin\tKd\tKd high\tKd low\tPRD-1177\t250 pM\t340 pM\t130 pM\nTABLE 13: Adnectin\tKd\tKd high\tKd low\tATI-1338\t850 pM\t1400 pM\t330 pM\nIn the HTRF competition binding assay, potencies ranged from IC50=1.5 nM to >100 nM (Table 14).\nMost positions tolerated alanine substitution in the HTRF assay to some degree, with the exception of Gly55, Arg56, and Gly57 of the DE loop, for which binding was drastically reduced (IC50s>100 nM).\nA lesser effect occurred in positions Gly30 of the BC loop, and Val80, Thr81, and Tyr88 of the FG loop, which still showed binding but with a >10-fold increase in IC50 relative to the parental sequence (“WT”).\nIn the ARE-luciferase cell-based assay, potency of mutants ranged from IC50=0.6 nM to >100 nM (Table 14).\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tWT parent\t1\t0.3\t0.6\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tBC\tS25A\t1\t0.82\t2.9\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tBC\tL26A\t1\t2.3\t16\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tBC\tP27A\t1\t1.0\t10\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tBC\tH28A\t1\t0.86\t6.2\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tBC\tQ29A\t1\t0.71\t1.5\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tBC\tG30A\t2\t5\t14.0\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tBC\tK31A\t1\t0.62\t2.2\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tBC\tN33A\t1\t2.09\t9.8\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tDE\tG55A\t2\t>100\t>100\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tDE\tR56A\t1\t55\t>100\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tDE\tG57A\t1\t>100\t>100\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tDE\tV58A\t2\t1.63\t3.3\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tFG\tV80A\t1\t14.0\t>100\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tFG\tT81A\t1\t4.93\t2.0\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tFG\tD82A\t1\t0.81\t1.8\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tFG\tT83A\t1\t1.31\t1.8\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tFG\tG84A\t1\t2.03\t3.6\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tFG\tY85A\t1\t2.05\t5.5\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tFG\tL86A\t2\t1.41\t2.0\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tFG\tK87A\t1\t0.82\t2.0\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tFG\tY88A\t1\t11\t>100\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tFG\tK89A\t1\t0.71\t1.6"
    },
    {
        "molecule_name": "D82A",
        "protein_target_name": "myostatin",
        "binding_metric": "IC50",
        "value": "1.8",
        "unit": "nM",
        "is_logarithmic": false,
        "raw_mentions": "Here are the extracted sentences/rows that meet the criteria:\n\n\nThe global Kd analysis shown in Table 13 gives a Kd of 170 pM with a 95% confidence interval of 330-60 pM.\nThese analyses indicate that PRD-1177 binds myostatin with a global Kd value of 250 pM and a 95% confidence interval of 340-130 pM (Table 13).\nATI-1338 binds myostatin with a global Kd value of 850 pM and a 95% confidence interval of 1400-330 pM.\nTABLE 13: Adnectin\tKd\tKd high\tKd low\tPRD-1474\t170 pM\t330 pM\t60 pM\nTABLE 13: Adnectin\tKd\tKd high\tKd low\tPRD-1177\t250 pM\t340 pM\t130 pM\nTABLE 13: Adnectin\tKd\tKd high\tKd low\tATI-1338\t850 pM\t1400 pM\t330 pM\nIn the HTRF competition binding assay, potencies ranged from IC50=1.5 nM to >100 nM (Table 14).\nMost positions tolerated alanine substitution in the HTRF assay to some degree, with the exception of Gly55, Arg56, and Gly57 of the DE loop, for which binding was drastically reduced (IC50s>100 nM).\nA lesser effect occurred in positions Gly30 of the BC loop, and Val80, Thr81, and Tyr88 of the FG loop, which still showed binding but with a >10-fold increase in IC50 relative to the parental sequence (“WT”).\nIn the ARE-luciferase cell-based assay, potency of mutants ranged from IC50=0.6 nM to >100 nM (Table 14).\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tWT parent\t1\t0.3\t0.6\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tBC\tS25A\t1\t0.82\t2.9\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tBC\tL26A\t1\t2.3\t16\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tBC\tP27A\t1\t1.0\t10\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tBC\tH28A\t1\t0.86\t6.2\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tBC\tQ29A\t1\t0.71\t1.5\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tBC\tG30A\t2\t5\t14.0\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tBC\tK31A\t1\t0.62\t2.2\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tBC\tN33A\t1\t2.09\t9.8\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tDE\tG55A\t2\t>100\t>100\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tDE\tR56A\t1\t55\t>100\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tDE\tG57A\t1\t>100\t>100\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tDE\tV58A\t2\t1.63\t3.3\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tFG\tV80A\t1\t14.0\t>100\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tFG\tT81A\t1\t4.93\t2.0\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tFG\tD82A\t1\t0.81\t1.8\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tFG\tT83A\t1\t1.31\t1.8\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tFG\tG84A\t1\t2.03\t3.6\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tFG\tY85A\t1\t2.05\t5.5\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tFG\tL86A\t2\t1.41\t2.0\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tFG\tK87A\t1\t0.82\t2.0\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tFG\tY88A\t1\t11\t>100\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tFG\tK89A\t1\t0.71\t1.6"
    },
    {
        "molecule_name": "T83A",
        "protein_target_name": "myostatin",
        "binding_metric": "IC50",
        "value": "1.31",
        "unit": "nM",
        "is_logarithmic": false,
        "raw_mentions": "Here are the extracted sentences/rows that meet the criteria:\n\n\nThe global Kd analysis shown in Table 13 gives a Kd of 170 pM with a 95% confidence interval of 330-60 pM.\nThese analyses indicate that PRD-1177 binds myostatin with a global Kd value of 250 pM and a 95% confidence interval of 340-130 pM (Table 13).\nATI-1338 binds myostatin with a global Kd value of 850 pM and a 95% confidence interval of 1400-330 pM.\nTABLE 13: Adnectin\tKd\tKd high\tKd low\tPRD-1474\t170 pM\t330 pM\t60 pM\nTABLE 13: Adnectin\tKd\tKd high\tKd low\tPRD-1177\t250 pM\t340 pM\t130 pM\nTABLE 13: Adnectin\tKd\tKd high\tKd low\tATI-1338\t850 pM\t1400 pM\t330 pM\nIn the HTRF competition binding assay, potencies ranged from IC50=1.5 nM to >100 nM (Table 14).\nMost positions tolerated alanine substitution in the HTRF assay to some degree, with the exception of Gly55, Arg56, and Gly57 of the DE loop, for which binding was drastically reduced (IC50s>100 nM).\nA lesser effect occurred in positions Gly30 of the BC loop, and Val80, Thr81, and Tyr88 of the FG loop, which still showed binding but with a >10-fold increase in IC50 relative to the parental sequence (“WT”).\nIn the ARE-luciferase cell-based assay, potency of mutants ranged from IC50=0.6 nM to >100 nM (Table 14).\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tWT parent\t1\t0.3\t0.6\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tBC\tS25A\t1\t0.82\t2.9\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tBC\tL26A\t1\t2.3\t16\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tBC\tP27A\t1\t1.0\t10\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tBC\tH28A\t1\t0.86\t6.2\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tBC\tQ29A\t1\t0.71\t1.5\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tBC\tG30A\t2\t5\t14.0\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tBC\tK31A\t1\t0.62\t2.2\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tBC\tN33A\t1\t2.09\t9.8\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tDE\tG55A\t2\t>100\t>100\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tDE\tR56A\t1\t55\t>100\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tDE\tG57A\t1\t>100\t>100\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tDE\tV58A\t2\t1.63\t3.3\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tFG\tV80A\t1\t14.0\t>100\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tFG\tT81A\t1\t4.93\t2.0\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tFG\tD82A\t1\t0.81\t1.8\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tFG\tT83A\t1\t1.31\t1.8\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tFG\tG84A\t1\t2.03\t3.6\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tFG\tY85A\t1\t2.05\t5.5\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tFG\tL86A\t2\t1.41\t2.0\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tFG\tK87A\t1\t0.82\t2.0\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tFG\tY88A\t1\t11\t>100\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tFG\tK89A\t1\t0.71\t1.6"
    },
    {
        "molecule_name": "T83A",
        "protein_target_name": "myostatin",
        "binding_metric": "IC50",
        "value": "1.8",
        "unit": "nM",
        "is_logarithmic": false,
        "raw_mentions": "Here are the extracted sentences/rows that meet the criteria:\n\n\nThe global Kd analysis shown in Table 13 gives a Kd of 170 pM with a 95% confidence interval of 330-60 pM.\nThese analyses indicate that PRD-1177 binds myostatin with a global Kd value of 250 pM and a 95% confidence interval of 340-130 pM (Table 13).\nATI-1338 binds myostatin with a global Kd value of 850 pM and a 95% confidence interval of 1400-330 pM.\nTABLE 13: Adnectin\tKd\tKd high\tKd low\tPRD-1474\t170 pM\t330 pM\t60 pM\nTABLE 13: Adnectin\tKd\tKd high\tKd low\tPRD-1177\t250 pM\t340 pM\t130 pM\nTABLE 13: Adnectin\tKd\tKd high\tKd low\tATI-1338\t850 pM\t1400 pM\t330 pM\nIn the HTRF competition binding assay, potencies ranged from IC50=1.5 nM to >100 nM (Table 14).\nMost positions tolerated alanine substitution in the HTRF assay to some degree, with the exception of Gly55, Arg56, and Gly57 of the DE loop, for which binding was drastically reduced (IC50s>100 nM).\nA lesser effect occurred in positions Gly30 of the BC loop, and Val80, Thr81, and Tyr88 of the FG loop, which still showed binding but with a >10-fold increase in IC50 relative to the parental sequence (“WT”).\nIn the ARE-luciferase cell-based assay, potency of mutants ranged from IC50=0.6 nM to >100 nM (Table 14).\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tWT parent\t1\t0.3\t0.6\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tBC\tS25A\t1\t0.82\t2.9\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tBC\tL26A\t1\t2.3\t16\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tBC\tP27A\t1\t1.0\t10\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tBC\tH28A\t1\t0.86\t6.2\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tBC\tQ29A\t1\t0.71\t1.5\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tBC\tG30A\t2\t5\t14.0\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tBC\tK31A\t1\t0.62\t2.2\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tBC\tN33A\t1\t2.09\t9.8\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tDE\tG55A\t2\t>100\t>100\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tDE\tR56A\t1\t55\t>100\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tDE\tG57A\t1\t>100\t>100\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tDE\tV58A\t2\t1.63\t3.3\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tFG\tV80A\t1\t14.0\t>100\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tFG\tT81A\t1\t4.93\t2.0\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tFG\tD82A\t1\t0.81\t1.8\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tFG\tT83A\t1\t1.31\t1.8\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tFG\tG84A\t1\t2.03\t3.6\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tFG\tY85A\t1\t2.05\t5.5\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tFG\tL86A\t2\t1.41\t2.0\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tFG\tK87A\t1\t0.82\t2.0\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tFG\tY88A\t1\t11\t>100\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tFG\tK89A\t1\t0.71\t1.6"
    },
    {
        "molecule_name": "G84A",
        "protein_target_name": "myostatin",
        "binding_metric": "IC50",
        "value": "2.03",
        "unit": "nM",
        "is_logarithmic": false,
        "raw_mentions": "Here are the extracted sentences/rows that meet the criteria:\n\n\nThe global Kd analysis shown in Table 13 gives a Kd of 170 pM with a 95% confidence interval of 330-60 pM.\nThese analyses indicate that PRD-1177 binds myostatin with a global Kd value of 250 pM and a 95% confidence interval of 340-130 pM (Table 13).\nATI-1338 binds myostatin with a global Kd value of 850 pM and a 95% confidence interval of 1400-330 pM.\nTABLE 13: Adnectin\tKd\tKd high\tKd low\tPRD-1474\t170 pM\t330 pM\t60 pM\nTABLE 13: Adnectin\tKd\tKd high\tKd low\tPRD-1177\t250 pM\t340 pM\t130 pM\nTABLE 13: Adnectin\tKd\tKd high\tKd low\tATI-1338\t850 pM\t1400 pM\t330 pM\nIn the HTRF competition binding assay, potencies ranged from IC50=1.5 nM to >100 nM (Table 14).\nMost positions tolerated alanine substitution in the HTRF assay to some degree, with the exception of Gly55, Arg56, and Gly57 of the DE loop, for which binding was drastically reduced (IC50s>100 nM).\nA lesser effect occurred in positions Gly30 of the BC loop, and Val80, Thr81, and Tyr88 of the FG loop, which still showed binding but with a >10-fold increase in IC50 relative to the parental sequence (“WT”).\nIn the ARE-luciferase cell-based assay, potency of mutants ranged from IC50=0.6 nM to >100 nM (Table 14).\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tWT parent\t1\t0.3\t0.6\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tBC\tS25A\t1\t0.82\t2.9\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tBC\tL26A\t1\t2.3\t16\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tBC\tP27A\t1\t1.0\t10\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tBC\tH28A\t1\t0.86\t6.2\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tBC\tQ29A\t1\t0.71\t1.5\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tBC\tG30A\t2\t5\t14.0\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tBC\tK31A\t1\t0.62\t2.2\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tBC\tN33A\t1\t2.09\t9.8\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tDE\tG55A\t2\t>100\t>100\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tDE\tR56A\t1\t55\t>100\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tDE\tG57A\t1\t>100\t>100\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tDE\tV58A\t2\t1.63\t3.3\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tFG\tV80A\t1\t14.0\t>100\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tFG\tT81A\t1\t4.93\t2.0\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tFG\tD82A\t1\t0.81\t1.8\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tFG\tT83A\t1\t1.31\t1.8\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tFG\tG84A\t1\t2.03\t3.6\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tFG\tY85A\t1\t2.05\t5.5\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tFG\tL86A\t2\t1.41\t2.0\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tFG\tK87A\t1\t0.82\t2.0\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tFG\tY88A\t1\t11\t>100\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tFG\tK89A\t1\t0.71\t1.6"
    },
    {
        "molecule_name": "G84A",
        "protein_target_name": "myostatin",
        "binding_metric": "IC50",
        "value": "3.6",
        "unit": "nM",
        "is_logarithmic": false,
        "raw_mentions": "Here are the extracted sentences/rows that meet the criteria:\n\n\nThe global Kd analysis shown in Table 13 gives a Kd of 170 pM with a 95% confidence interval of 330-60 pM.\nThese analyses indicate that PRD-1177 binds myostatin with a global Kd value of 250 pM and a 95% confidence interval of 340-130 pM (Table 13).\nATI-1338 binds myostatin with a global Kd value of 850 pM and a 95% confidence interval of 1400-330 pM.\nTABLE 13: Adnectin\tKd\tKd high\tKd low\tPRD-1474\t170 pM\t330 pM\t60 pM\nTABLE 13: Adnectin\tKd\tKd high\tKd low\tPRD-1177\t250 pM\t340 pM\t130 pM\nTABLE 13: Adnectin\tKd\tKd high\tKd low\tATI-1338\t850 pM\t1400 pM\t330 pM\nIn the HTRF competition binding assay, potencies ranged from IC50=1.5 nM to >100 nM (Table 14).\nMost positions tolerated alanine substitution in the HTRF assay to some degree, with the exception of Gly55, Arg56, and Gly57 of the DE loop, for which binding was drastically reduced (IC50s>100 nM).\nA lesser effect occurred in positions Gly30 of the BC loop, and Val80, Thr81, and Tyr88 of the FG loop, which still showed binding but with a >10-fold increase in IC50 relative to the parental sequence (“WT”).\nIn the ARE-luciferase cell-based assay, potency of mutants ranged from IC50=0.6 nM to >100 nM (Table 14).\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tWT parent\t1\t0.3\t0.6\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tBC\tS25A\t1\t0.82\t2.9\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tBC\tL26A\t1\t2.3\t16\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tBC\tP27A\t1\t1.0\t10\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tBC\tH28A\t1\t0.86\t6.2\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tBC\tQ29A\t1\t0.71\t1.5\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tBC\tG30A\t2\t5\t14.0\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tBC\tK31A\t1\t0.62\t2.2\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tBC\tN33A\t1\t2.09\t9.8\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tDE\tG55A\t2\t>100\t>100\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tDE\tR56A\t1\t55\t>100\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tDE\tG57A\t1\t>100\t>100\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tDE\tV58A\t2\t1.63\t3.3\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tFG\tV80A\t1\t14.0\t>100\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tFG\tT81A\t1\t4.93\t2.0\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tFG\tD82A\t1\t0.81\t1.8\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tFG\tT83A\t1\t1.31\t1.8\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tFG\tG84A\t1\t2.03\t3.6\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tFG\tY85A\t1\t2.05\t5.5\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tFG\tL86A\t2\t1.41\t2.0\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tFG\tK87A\t1\t0.82\t2.0\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tFG\tY88A\t1\t11\t>100\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tFG\tK89A\t1\t0.71\t1.6"
    },
    {
        "molecule_name": "Y85A",
        "protein_target_name": "myostatin",
        "binding_metric": "IC50",
        "value": "2.05",
        "unit": "nM",
        "is_logarithmic": false,
        "raw_mentions": "Here are the extracted sentences/rows that meet the criteria:\n\n\nThe global Kd analysis shown in Table 13 gives a Kd of 170 pM with a 95% confidence interval of 330-60 pM.\nThese analyses indicate that PRD-1177 binds myostatin with a global Kd value of 250 pM and a 95% confidence interval of 340-130 pM (Table 13).\nATI-1338 binds myostatin with a global Kd value of 850 pM and a 95% confidence interval of 1400-330 pM.\nTABLE 13: Adnectin\tKd\tKd high\tKd low\tPRD-1474\t170 pM\t330 pM\t60 pM\nTABLE 13: Adnectin\tKd\tKd high\tKd low\tPRD-1177\t250 pM\t340 pM\t130 pM\nTABLE 13: Adnectin\tKd\tKd high\tKd low\tATI-1338\t850 pM\t1400 pM\t330 pM\nIn the HTRF competition binding assay, potencies ranged from IC50=1.5 nM to >100 nM (Table 14).\nMost positions tolerated alanine substitution in the HTRF assay to some degree, with the exception of Gly55, Arg56, and Gly57 of the DE loop, for which binding was drastically reduced (IC50s>100 nM).\nA lesser effect occurred in positions Gly30 of the BC loop, and Val80, Thr81, and Tyr88 of the FG loop, which still showed binding but with a >10-fold increase in IC50 relative to the parental sequence (“WT”).\nIn the ARE-luciferase cell-based assay, potency of mutants ranged from IC50=0.6 nM to >100 nM (Table 14).\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tWT parent\t1\t0.3\t0.6\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tBC\tS25A\t1\t0.82\t2.9\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tBC\tL26A\t1\t2.3\t16\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tBC\tP27A\t1\t1.0\t10\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tBC\tH28A\t1\t0.86\t6.2\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tBC\tQ29A\t1\t0.71\t1.5\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tBC\tG30A\t2\t5\t14.0\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tBC\tK31A\t1\t0.62\t2.2\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tBC\tN33A\t1\t2.09\t9.8\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tDE\tG55A\t2\t>100\t>100\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tDE\tR56A\t1\t55\t>100\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tDE\tG57A\t1\t>100\t>100\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tDE\tV58A\t2\t1.63\t3.3\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tFG\tV80A\t1\t14.0\t>100\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tFG\tT81A\t1\t4.93\t2.0\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tFG\tD82A\t1\t0.81\t1.8\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tFG\tT83A\t1\t1.31\t1.8\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tFG\tG84A\t1\t2.03\t3.6\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tFG\tY85A\t1\t2.05\t5.5\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tFG\tL86A\t2\t1.41\t2.0\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tFG\tK87A\t1\t0.82\t2.0\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tFG\tY88A\t1\t11\t>100\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tFG\tK89A\t1\t0.71\t1.6"
    },
    {
        "molecule_name": "Y85A",
        "protein_target_name": "myostatin",
        "binding_metric": "IC50",
        "value": "5.5",
        "unit": "nM",
        "is_logarithmic": false,
        "raw_mentions": "Here are the extracted sentences/rows that meet the criteria:\n\n\nThe global Kd analysis shown in Table 13 gives a Kd of 170 pM with a 95% confidence interval of 330-60 pM.\nThese analyses indicate that PRD-1177 binds myostatin with a global Kd value of 250 pM and a 95% confidence interval of 340-130 pM (Table 13).\nATI-1338 binds myostatin with a global Kd value of 850 pM and a 95% confidence interval of 1400-330 pM.\nTABLE 13: Adnectin\tKd\tKd high\tKd low\tPRD-1474\t170 pM\t330 pM\t60 pM\nTABLE 13: Adnectin\tKd\tKd high\tKd low\tPRD-1177\t250 pM\t340 pM\t130 pM\nTABLE 13: Adnectin\tKd\tKd high\tKd low\tATI-1338\t850 pM\t1400 pM\t330 pM\nIn the HTRF competition binding assay, potencies ranged from IC50=1.5 nM to >100 nM (Table 14).\nMost positions tolerated alanine substitution in the HTRF assay to some degree, with the exception of Gly55, Arg56, and Gly57 of the DE loop, for which binding was drastically reduced (IC50s>100 nM).\nA lesser effect occurred in positions Gly30 of the BC loop, and Val80, Thr81, and Tyr88 of the FG loop, which still showed binding but with a >10-fold increase in IC50 relative to the parental sequence (“WT”).\nIn the ARE-luciferase cell-based assay, potency of mutants ranged from IC50=0.6 nM to >100 nM (Table 14).\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tWT parent\t1\t0.3\t0.6\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tBC\tS25A\t1\t0.82\t2.9\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tBC\tL26A\t1\t2.3\t16\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tBC\tP27A\t1\t1.0\t10\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tBC\tH28A\t1\t0.86\t6.2\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tBC\tQ29A\t1\t0.71\t1.5\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tBC\tG30A\t2\t5\t14.0\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tBC\tK31A\t1\t0.62\t2.2\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tBC\tN33A\t1\t2.09\t9.8\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tDE\tG55A\t2\t>100\t>100\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tDE\tR56A\t1\t55\t>100\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tDE\tG57A\t1\t>100\t>100\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tDE\tV58A\t2\t1.63\t3.3\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tFG\tV80A\t1\t14.0\t>100\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tFG\tT81A\t1\t4.93\t2.0\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tFG\tD82A\t1\t0.81\t1.8\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tFG\tT83A\t1\t1.31\t1.8\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tFG\tG84A\t1\t2.03\t3.6\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tFG\tY85A\t1\t2.05\t5.5\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tFG\tL86A\t2\t1.41\t2.0\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tFG\tK87A\t1\t0.82\t2.0\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tFG\tY88A\t1\t11\t>100\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tFG\tK89A\t1\t0.71\t1.6"
    },
    {
        "molecule_name": "L86A",
        "protein_target_name": "myostatin",
        "binding_metric": "IC50",
        "value": "1.41",
        "unit": "nM",
        "is_logarithmic": false,
        "raw_mentions": "Here are the extracted sentences/rows that meet the criteria:\n\n\nThe global Kd analysis shown in Table 13 gives a Kd of 170 pM with a 95% confidence interval of 330-60 pM.\nThese analyses indicate that PRD-1177 binds myostatin with a global Kd value of 250 pM and a 95% confidence interval of 340-130 pM (Table 13).\nATI-1338 binds myostatin with a global Kd value of 850 pM and a 95% confidence interval of 1400-330 pM.\nTABLE 13: Adnectin\tKd\tKd high\tKd low\tPRD-1474\t170 pM\t330 pM\t60 pM\nTABLE 13: Adnectin\tKd\tKd high\tKd low\tPRD-1177\t250 pM\t340 pM\t130 pM\nTABLE 13: Adnectin\tKd\tKd high\tKd low\tATI-1338\t850 pM\t1400 pM\t330 pM\nIn the HTRF competition binding assay, potencies ranged from IC50=1.5 nM to >100 nM (Table 14).\nMost positions tolerated alanine substitution in the HTRF assay to some degree, with the exception of Gly55, Arg56, and Gly57 of the DE loop, for which binding was drastically reduced (IC50s>100 nM).\nA lesser effect occurred in positions Gly30 of the BC loop, and Val80, Thr81, and Tyr88 of the FG loop, which still showed binding but with a >10-fold increase in IC50 relative to the parental sequence (“WT”).\nIn the ARE-luciferase cell-based assay, potency of mutants ranged from IC50=0.6 nM to >100 nM (Table 14).\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tWT parent\t1\t0.3\t0.6\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tBC\tS25A\t1\t0.82\t2.9\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tBC\tL26A\t1\t2.3\t16\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tBC\tP27A\t1\t1.0\t10\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tBC\tH28A\t1\t0.86\t6.2\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tBC\tQ29A\t1\t0.71\t1.5\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tBC\tG30A\t2\t5\t14.0\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tBC\tK31A\t1\t0.62\t2.2\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tBC\tN33A\t1\t2.09\t9.8\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tDE\tG55A\t2\t>100\t>100\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tDE\tR56A\t1\t55\t>100\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tDE\tG57A\t1\t>100\t>100\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tDE\tV58A\t2\t1.63\t3.3\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tFG\tV80A\t1\t14.0\t>100\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tFG\tT81A\t1\t4.93\t2.0\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tFG\tD82A\t1\t0.81\t1.8\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tFG\tT83A\t1\t1.31\t1.8\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tFG\tG84A\t1\t2.03\t3.6\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tFG\tY85A\t1\t2.05\t5.5\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tFG\tL86A\t2\t1.41\t2.0\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tFG\tK87A\t1\t0.82\t2.0\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tFG\tY88A\t1\t11\t>100\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tFG\tK89A\t1\t0.71\t1.6"
    },
    {
        "molecule_name": "L86A",
        "protein_target_name": "myostatin",
        "binding_metric": "IC50",
        "value": "2.0",
        "unit": "nM",
        "is_logarithmic": false,
        "raw_mentions": "Here are the extracted sentences/rows that meet the criteria:\n\n\nThe global Kd analysis shown in Table 13 gives a Kd of 170 pM with a 95% confidence interval of 330-60 pM.\nThese analyses indicate that PRD-1177 binds myostatin with a global Kd value of 250 pM and a 95% confidence interval of 340-130 pM (Table 13).\nATI-1338 binds myostatin with a global Kd value of 850 pM and a 95% confidence interval of 1400-330 pM.\nTABLE 13: Adnectin\tKd\tKd high\tKd low\tPRD-1474\t170 pM\t330 pM\t60 pM\nTABLE 13: Adnectin\tKd\tKd high\tKd low\tPRD-1177\t250 pM\t340 pM\t130 pM\nTABLE 13: Adnectin\tKd\tKd high\tKd low\tATI-1338\t850 pM\t1400 pM\t330 pM\nIn the HTRF competition binding assay, potencies ranged from IC50=1.5 nM to >100 nM (Table 14).\nMost positions tolerated alanine substitution in the HTRF assay to some degree, with the exception of Gly55, Arg56, and Gly57 of the DE loop, for which binding was drastically reduced (IC50s>100 nM).\nA lesser effect occurred in positions Gly30 of the BC loop, and Val80, Thr81, and Tyr88 of the FG loop, which still showed binding but with a >10-fold increase in IC50 relative to the parental sequence (“WT”).\nIn the ARE-luciferase cell-based assay, potency of mutants ranged from IC50=0.6 nM to >100 nM (Table 14).\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tWT parent\t1\t0.3\t0.6\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tBC\tS25A\t1\t0.82\t2.9\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tBC\tL26A\t1\t2.3\t16\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tBC\tP27A\t1\t1.0\t10\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tBC\tH28A\t1\t0.86\t6.2\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tBC\tQ29A\t1\t0.71\t1.5\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tBC\tG30A\t2\t5\t14.0\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tBC\tK31A\t1\t0.62\t2.2\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tBC\tN33A\t1\t2.09\t9.8\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tDE\tG55A\t2\t>100\t>100\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tDE\tR56A\t1\t55\t>100\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tDE\tG57A\t1\t>100\t>100\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tDE\tV58A\t2\t1.63\t3.3\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tFG\tV80A\t1\t14.0\t>100\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tFG\tT81A\t1\t4.93\t2.0\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tFG\tD82A\t1\t0.81\t1.8\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tFG\tT83A\t1\t1.31\t1.8\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tFG\tG84A\t1\t2.03\t3.6\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tFG\tY85A\t1\t2.05\t5.5\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tFG\tL86A\t2\t1.41\t2.0\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tFG\tK87A\t1\t0.82\t2.0\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tFG\tY88A\t1\t11\t>100\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tFG\tK89A\t1\t0.71\t1.6"
    },
    {
        "molecule_name": "K87A",
        "protein_target_name": "myostatin",
        "binding_metric": "IC50",
        "value": "0.82",
        "unit": "nM",
        "is_logarithmic": false,
        "raw_mentions": "Here are the extracted sentences/rows that meet the criteria:\n\n\nThe global Kd analysis shown in Table 13 gives a Kd of 170 pM with a 95% confidence interval of 330-60 pM.\nThese analyses indicate that PRD-1177 binds myostatin with a global Kd value of 250 pM and a 95% confidence interval of 340-130 pM (Table 13).\nATI-1338 binds myostatin with a global Kd value of 850 pM and a 95% confidence interval of 1400-330 pM.\nTABLE 13: Adnectin\tKd\tKd high\tKd low\tPRD-1474\t170 pM\t330 pM\t60 pM\nTABLE 13: Adnectin\tKd\tKd high\tKd low\tPRD-1177\t250 pM\t340 pM\t130 pM\nTABLE 13: Adnectin\tKd\tKd high\tKd low\tATI-1338\t850 pM\t1400 pM\t330 pM\nIn the HTRF competition binding assay, potencies ranged from IC50=1.5 nM to >100 nM (Table 14).\nMost positions tolerated alanine substitution in the HTRF assay to some degree, with the exception of Gly55, Arg56, and Gly57 of the DE loop, for which binding was drastically reduced (IC50s>100 nM).\nA lesser effect occurred in positions Gly30 of the BC loop, and Val80, Thr81, and Tyr88 of the FG loop, which still showed binding but with a >10-fold increase in IC50 relative to the parental sequence (“WT”).\nIn the ARE-luciferase cell-based assay, potency of mutants ranged from IC50=0.6 nM to >100 nM (Table 14).\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tWT parent\t1\t0.3\t0.6\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tBC\tS25A\t1\t0.82\t2.9\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tBC\tL26A\t1\t2.3\t16\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tBC\tP27A\t1\t1.0\t10\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tBC\tH28A\t1\t0.86\t6.2\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tBC\tQ29A\t1\t0.71\t1.5\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tBC\tG30A\t2\t5\t14.0\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tBC\tK31A\t1\t0.62\t2.2\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tBC\tN33A\t1\t2.09\t9.8\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tDE\tG55A\t2\t>100\t>100\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tDE\tR56A\t1\t55\t>100\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tDE\tG57A\t1\t>100\t>100\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tDE\tV58A\t2\t1.63\t3.3\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tFG\tV80A\t1\t14.0\t>100\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tFG\tT81A\t1\t4.93\t2.0\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tFG\tD82A\t1\t0.81\t1.8\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tFG\tT83A\t1\t1.31\t1.8\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tFG\tG84A\t1\t2.03\t3.6\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tFG\tY85A\t1\t2.05\t5.5\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tFG\tL86A\t2\t1.41\t2.0\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tFG\tK87A\t1\t0.82\t2.0\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tFG\tY88A\t1\t11\t>100\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tFG\tK89A\t1\t0.71\t1.6"
    },
    {
        "molecule_name": "K87A",
        "protein_target_name": "myostatin",
        "binding_metric": "IC50",
        "value": "2.0",
        "unit": "nM",
        "is_logarithmic": false,
        "raw_mentions": "Here are the extracted sentences/rows that meet the criteria:\n\n\nThe global Kd analysis shown in Table 13 gives a Kd of 170 pM with a 95% confidence interval of 330-60 pM.\nThese analyses indicate that PRD-1177 binds myostatin with a global Kd value of 250 pM and a 95% confidence interval of 340-130 pM (Table 13).\nATI-1338 binds myostatin with a global Kd value of 850 pM and a 95% confidence interval of 1400-330 pM.\nTABLE 13: Adnectin\tKd\tKd high\tKd low\tPRD-1474\t170 pM\t330 pM\t60 pM\nTABLE 13: Adnectin\tKd\tKd high\tKd low\tPRD-1177\t250 pM\t340 pM\t130 pM\nTABLE 13: Adnectin\tKd\tKd high\tKd low\tATI-1338\t850 pM\t1400 pM\t330 pM\nIn the HTRF competition binding assay, potencies ranged from IC50=1.5 nM to >100 nM (Table 14).\nMost positions tolerated alanine substitution in the HTRF assay to some degree, with the exception of Gly55, Arg56, and Gly57 of the DE loop, for which binding was drastically reduced (IC50s>100 nM).\nA lesser effect occurred in positions Gly30 of the BC loop, and Val80, Thr81, and Tyr88 of the FG loop, which still showed binding but with a >10-fold increase in IC50 relative to the parental sequence (“WT”).\nIn the ARE-luciferase cell-based assay, potency of mutants ranged from IC50=0.6 nM to >100 nM (Table 14).\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tWT parent\t1\t0.3\t0.6\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tBC\tS25A\t1\t0.82\t2.9\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tBC\tL26A\t1\t2.3\t16\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tBC\tP27A\t1\t1.0\t10\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tBC\tH28A\t1\t0.86\t6.2\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tBC\tQ29A\t1\t0.71\t1.5\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tBC\tG30A\t2\t5\t14.0\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tBC\tK31A\t1\t0.62\t2.2\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tBC\tN33A\t1\t2.09\t9.8\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tDE\tG55A\t2\t>100\t>100\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tDE\tR56A\t1\t55\t>100\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tDE\tG57A\t1\t>100\t>100\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tDE\tV58A\t2\t1.63\t3.3\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tFG\tV80A\t1\t14.0\t>100\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tFG\tT81A\t1\t4.93\t2.0\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tFG\tD82A\t1\t0.81\t1.8\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tFG\tT83A\t1\t1.31\t1.8\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tFG\tG84A\t1\t2.03\t3.6\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tFG\tY85A\t1\t2.05\t5.5\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tFG\tL86A\t2\t1.41\t2.0\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tFG\tK87A\t1\t0.82\t2.0\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tFG\tY88A\t1\t11\t>100\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tFG\tK89A\t1\t0.71\t1.6"
    },
    {
        "molecule_name": "Y88A",
        "protein_target_name": "myostatin",
        "binding_metric": "IC50",
        "value": "11",
        "unit": "nM",
        "is_logarithmic": false,
        "raw_mentions": "Here are the extracted sentences/rows that meet the criteria:\n\n\nThe global Kd analysis shown in Table 13 gives a Kd of 170 pM with a 95% confidence interval of 330-60 pM.\nThese analyses indicate that PRD-1177 binds myostatin with a global Kd value of 250 pM and a 95% confidence interval of 340-130 pM (Table 13).\nATI-1338 binds myostatin with a global Kd value of 850 pM and a 95% confidence interval of 1400-330 pM.\nTABLE 13: Adnectin\tKd\tKd high\tKd low\tPRD-1474\t170 pM\t330 pM\t60 pM\nTABLE 13: Adnectin\tKd\tKd high\tKd low\tPRD-1177\t250 pM\t340 pM\t130 pM\nTABLE 13: Adnectin\tKd\tKd high\tKd low\tATI-1338\t850 pM\t1400 pM\t330 pM\nIn the HTRF competition binding assay, potencies ranged from IC50=1.5 nM to >100 nM (Table 14).\nMost positions tolerated alanine substitution in the HTRF assay to some degree, with the exception of Gly55, Arg56, and Gly57 of the DE loop, for which binding was drastically reduced (IC50s>100 nM).\nA lesser effect occurred in positions Gly30 of the BC loop, and Val80, Thr81, and Tyr88 of the FG loop, which still showed binding but with a >10-fold increase in IC50 relative to the parental sequence (“WT”).\nIn the ARE-luciferase cell-based assay, potency of mutants ranged from IC50=0.6 nM to >100 nM (Table 14).\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tWT parent\t1\t0.3\t0.6\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tBC\tS25A\t1\t0.82\t2.9\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tBC\tL26A\t1\t2.3\t16\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tBC\tP27A\t1\t1.0\t10\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tBC\tH28A\t1\t0.86\t6.2\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tBC\tQ29A\t1\t0.71\t1.5\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tBC\tG30A\t2\t5\t14.0\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tBC\tK31A\t1\t0.62\t2.2\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tBC\tN33A\t1\t2.09\t9.8\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tDE\tG55A\t2\t>100\t>100\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tDE\tR56A\t1\t55\t>100\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tDE\tG57A\t1\t>100\t>100\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tDE\tV58A\t2\t1.63\t3.3\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tFG\tV80A\t1\t14.0\t>100\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tFG\tT81A\t1\t4.93\t2.0\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tFG\tD82A\t1\t0.81\t1.8\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tFG\tT83A\t1\t1.31\t1.8\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tFG\tG84A\t1\t2.03\t3.6\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tFG\tY85A\t1\t2.05\t5.5\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tFG\tL86A\t2\t1.41\t2.0\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tFG\tK87A\t1\t0.82\t2.0\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tFG\tY88A\t1\t11\t>100\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tFG\tK89A\t1\t0.71\t1.6"
    },
    {
        "molecule_name": "Y88A",
        "protein_target_name": "myostatin",
        "binding_metric": "IC50",
        "value": ">100",
        "unit": "nM",
        "is_logarithmic": false,
        "raw_mentions": "Here are the extracted sentences/rows that meet the criteria:\n\n\nThe global Kd analysis shown in Table 13 gives a Kd of 170 pM with a 95% confidence interval of 330-60 pM.\nThese analyses indicate that PRD-1177 binds myostatin with a global Kd value of 250 pM and a 95% confidence interval of 340-130 pM (Table 13).\nATI-1338 binds myostatin with a global Kd value of 850 pM and a 95% confidence interval of 1400-330 pM.\nTABLE 13: Adnectin\tKd\tKd high\tKd low\tPRD-1474\t170 pM\t330 pM\t60 pM\nTABLE 13: Adnectin\tKd\tKd high\tKd low\tPRD-1177\t250 pM\t340 pM\t130 pM\nTABLE 13: Adnectin\tKd\tKd high\tKd low\tATI-1338\t850 pM\t1400 pM\t330 pM\nIn the HTRF competition binding assay, potencies ranged from IC50=1.5 nM to >100 nM (Table 14).\nMost positions tolerated alanine substitution in the HTRF assay to some degree, with the exception of Gly55, Arg56, and Gly57 of the DE loop, for which binding was drastically reduced (IC50s>100 nM).\nA lesser effect occurred in positions Gly30 of the BC loop, and Val80, Thr81, and Tyr88 of the FG loop, which still showed binding but with a >10-fold increase in IC50 relative to the parental sequence (“WT”).\nIn the ARE-luciferase cell-based assay, potency of mutants ranged from IC50=0.6 nM to >100 nM (Table 14).\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tWT parent\t1\t0.3\t0.6\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tBC\tS25A\t1\t0.82\t2.9\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tBC\tL26A\t1\t2.3\t16\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tBC\tP27A\t1\t1.0\t10\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tBC\tH28A\t1\t0.86\t6.2\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tBC\tQ29A\t1\t0.71\t1.5\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tBC\tG30A\t2\t5\t14.0\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tBC\tK31A\t1\t0.62\t2.2\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tBC\tN33A\t1\t2.09\t9.8\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tDE\tG55A\t2\t>100\t>100\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tDE\tR56A\t1\t55\t>100\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tDE\tG57A\t1\t>100\t>100\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tDE\tV58A\t2\t1.63\t3.3\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tFG\tV80A\t1\t14.0\t>100\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tFG\tT81A\t1\t4.93\t2.0\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tFG\tD82A\t1\t0.81\t1.8\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tFG\tT83A\t1\t1.31\t1.8\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tFG\tG84A\t1\t2.03\t3.6\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tFG\tY85A\t1\t2.05\t5.5\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tFG\tL86A\t2\t1.41\t2.0\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tFG\tK87A\t1\t0.82\t2.0\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tFG\tY88A\t1\t11\t>100\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tFG\tK89A\t1\t0.71\t1.6"
    },
    {
        "molecule_name": "K89A",
        "protein_target_name": "myostatin",
        "binding_metric": "IC50",
        "value": "0.71",
        "unit": "nM",
        "is_logarithmic": false,
        "raw_mentions": "Here are the extracted sentences/rows that meet the criteria:\n\n\nThe global Kd analysis shown in Table 13 gives a Kd of 170 pM with a 95% confidence interval of 330-60 pM.\nThese analyses indicate that PRD-1177 binds myostatin with a global Kd value of 250 pM and a 95% confidence interval of 340-130 pM (Table 13).\nATI-1338 binds myostatin with a global Kd value of 850 pM and a 95% confidence interval of 1400-330 pM.\nTABLE 13: Adnectin\tKd\tKd high\tKd low\tPRD-1474\t170 pM\t330 pM\t60 pM\nTABLE 13: Adnectin\tKd\tKd high\tKd low\tPRD-1177\t250 pM\t340 pM\t130 pM\nTABLE 13: Adnectin\tKd\tKd high\tKd low\tATI-1338\t850 pM\t1400 pM\t330 pM\nIn the HTRF competition binding assay, potencies ranged from IC50=1.5 nM to >100 nM (Table 14).\nMost positions tolerated alanine substitution in the HTRF assay to some degree, with the exception of Gly55, Arg56, and Gly57 of the DE loop, for which binding was drastically reduced (IC50s>100 nM).\nA lesser effect occurred in positions Gly30 of the BC loop, and Val80, Thr81, and Tyr88 of the FG loop, which still showed binding but with a >10-fold increase in IC50 relative to the parental sequence (“WT”).\nIn the ARE-luciferase cell-based assay, potency of mutants ranged from IC50=0.6 nM to >100 nM (Table 14).\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tWT parent\t1\t0.3\t0.6\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tBC\tS25A\t1\t0.82\t2.9\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tBC\tL26A\t1\t2.3\t16\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tBC\tP27A\t1\t1.0\t10\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tBC\tH28A\t1\t0.86\t6.2\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tBC\tQ29A\t1\t0.71\t1.5\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tBC\tG30A\t2\t5\t14.0\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tBC\tK31A\t1\t0.62\t2.2\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tBC\tN33A\t1\t2.09\t9.8\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tDE\tG55A\t2\t>100\t>100\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tDE\tR56A\t1\t55\t>100\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tDE\tG57A\t1\t>100\t>100\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tDE\tV58A\t2\t1.63\t3.3\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tFG\tV80A\t1\t14.0\t>100\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tFG\tT81A\t1\t4.93\t2.0\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tFG\tD82A\t1\t0.81\t1.8\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tFG\tT83A\t1\t1.31\t1.8\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tFG\tG84A\t1\t2.03\t3.6\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tFG\tY85A\t1\t2.05\t5.5\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tFG\tL86A\t2\t1.41\t2.0\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tFG\tK87A\t1\t0.82\t2.0\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tFG\tY88A\t1\t11\t>100\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tFG\tK89A\t1\t0.71\t1.6"
    },
    {
        "molecule_name": "K89A",
        "protein_target_name": "myostatin",
        "binding_metric": "IC50",
        "value": "1.6",
        "unit": "nM",
        "is_logarithmic": false,
        "raw_mentions": "Here are the extracted sentences/rows that meet the criteria:\n\n\nThe global Kd analysis shown in Table 13 gives a Kd of 170 pM with a 95% confidence interval of 330-60 pM.\nThese analyses indicate that PRD-1177 binds myostatin with a global Kd value of 250 pM and a 95% confidence interval of 340-130 pM (Table 13).\nATI-1338 binds myostatin with a global Kd value of 850 pM and a 95% confidence interval of 1400-330 pM.\nTABLE 13: Adnectin\tKd\tKd high\tKd low\tPRD-1474\t170 pM\t330 pM\t60 pM\nTABLE 13: Adnectin\tKd\tKd high\tKd low\tPRD-1177\t250 pM\t340 pM\t130 pM\nTABLE 13: Adnectin\tKd\tKd high\tKd low\tATI-1338\t850 pM\t1400 pM\t330 pM\nIn the HTRF competition binding assay, potencies ranged from IC50=1.5 nM to >100 nM (Table 14).\nMost positions tolerated alanine substitution in the HTRF assay to some degree, with the exception of Gly55, Arg56, and Gly57 of the DE loop, for which binding was drastically reduced (IC50s>100 nM).\nA lesser effect occurred in positions Gly30 of the BC loop, and Val80, Thr81, and Tyr88 of the FG loop, which still showed binding but with a >10-fold increase in IC50 relative to the parental sequence (“WT”).\nIn the ARE-luciferase cell-based assay, potency of mutants ranged from IC50=0.6 nM to >100 nM (Table 14).\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tWT parent\t1\t0.3\t0.6\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tBC\tS25A\t1\t0.82\t2.9\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tBC\tL26A\t1\t2.3\t16\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tBC\tP27A\t1\t1.0\t10\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tBC\tH28A\t1\t0.86\t6.2\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tBC\tQ29A\t1\t0.71\t1.5\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tBC\tG30A\t2\t5\t14.0\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tBC\tK31A\t1\t0.62\t2.2\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tBC\tN33A\t1\t2.09\t9.8\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tDE\tG55A\t2\t>100\t>100\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tDE\tR56A\t1\t55\t>100\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tDE\tG57A\t1\t>100\t>100\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tDE\tV58A\t2\t1.63\t3.3\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tFG\tV80A\t1\t14.0\t>100\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tFG\tT81A\t1\t4.93\t2.0\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tFG\tD82A\t1\t0.81\t1.8\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tFG\tT83A\t1\t1.31\t1.8\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tFG\tG84A\t1\t2.03\t3.6\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tFG\tY85A\t1\t2.05\t5.5\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tFG\tL86A\t2\t1.41\t2.0\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tFG\tK87A\t1\t0.82\t2.0\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tFG\tY88A\t1\t11\t>100\nTABLE 14: Myostatin HTRF\tMyostatin ARE-luc\tMutation\tSEC*\tIC50 (nM)\tIC50 (nM)\tFG\tK89A\t1\t0.71\t1.6"
    },
    {
        "molecule_name": "PRD-1177",
        "protein_target_name": "myostatin",
        "binding_metric": "Dose",
        "value": "2",
        "unit": "mg/kg",
        "is_logarithmic": false,
        "raw_mentions": "Here are the extracted sentences/rows that meet the criteria:\n\n\nThe biochemical HTRF IC50 was also plotted directly versus the NGS ER<sup>norm </sup>for each alanine mutant, as shown in FIG. 9.\nTABLE 16Pharmacokinetic Comparison of ThreePEGylated Formats for Adnectin 2987_H07PK ParametersATI-1338ATI-1339ATI-1341Dose (mg/kg)53.94Cmax/Dose547370113(nM/(mg/kg))Tmax (h)24244AUC/Dose32232.1(nM*hr/(mg/kg))t<sub>1/2 </sub>(h)253116\nTABLE 17Pharmacokinetic Comparison of Three Fc-fused anti-myostatin AdnectinsPK ParametersPRD-1177PRD-1286PRD-1474Dose (mg/kg)222Clearance0.0170.0160.014(mL/min/kg)Vdss (L/kg)0.0930.1900.054t<sub>1/2 </sub>(h)68172"
    },
    {
        "molecule_name": "PRD-1177",
        "protein_target_name": "myostatin",
        "binding_metric": "Clearance",
        "value": "0.017",
        "unit": "mL/min/kg",
        "is_logarithmic": false,
        "raw_mentions": "Here are the extracted sentences/rows that meet the criteria:\n\n\nThe biochemical HTRF IC50 was also plotted directly versus the NGS ER<sup>norm </sup>for each alanine mutant, as shown in FIG. 9.\nTABLE 16Pharmacokinetic Comparison of ThreePEGylated Formats for Adnectin 2987_H07PK ParametersATI-1338ATI-1339ATI-1341Dose (mg/kg)53.94Cmax/Dose547370113(nM/(mg/kg))Tmax (h)24244AUC/Dose32232.1(nM*hr/(mg/kg))t<sub>1/2 </sub>(h)253116\nTABLE 17Pharmacokinetic Comparison of Three Fc-fused anti-myostatin AdnectinsPK ParametersPRD-1177PRD-1286PRD-1474Dose (mg/kg)222Clearance0.0170.0160.014(mL/min/kg)Vdss (L/kg)0.0930.1900.054t<sub>1/2 </sub>(h)68172"
    },
    {
        "molecule_name": "PRD-1177",
        "protein_target_name": "myostatin",
        "binding_metric": "Vdss",
        "value": "0.093",
        "unit": "L/kg",
        "is_logarithmic": false,
        "raw_mentions": "Here are the extracted sentences/rows that meet the criteria:\n\n\nThe biochemical HTRF IC50 was also plotted directly versus the NGS ER<sup>norm </sup>for each alanine mutant, as shown in FIG. 9.\nTABLE 16Pharmacokinetic Comparison of ThreePEGylated Formats for Adnectin 2987_H07PK ParametersATI-1338ATI-1339ATI-1341Dose (mg/kg)53.94Cmax/Dose547370113(nM/(mg/kg))Tmax (h)24244AUC/Dose32232.1(nM*hr/(mg/kg))t<sub>1/2 </sub>(h)253116\nTABLE 17Pharmacokinetic Comparison of Three Fc-fused anti-myostatin AdnectinsPK ParametersPRD-1177PRD-1286PRD-1474Dose (mg/kg)222Clearance0.0170.0160.014(mL/min/kg)Vdss (L/kg)0.0930.1900.054t<sub>1/2 </sub>(h)68172"
    },
    {
        "molecule_name": "PRD-1177",
        "protein_target_name": "myostatin",
        "binding_metric": "t1/2",
        "value": "68",
        "unit": "h",
        "is_logarithmic": false,
        "raw_mentions": "Here are the extracted sentences/rows that meet the criteria:\n\n\nThe biochemical HTRF IC50 was also plotted directly versus the NGS ER<sup>norm </sup>for each alanine mutant, as shown in FIG. 9.\nTABLE 16Pharmacokinetic Comparison of ThreePEGylated Formats for Adnectin 2987_H07PK ParametersATI-1338ATI-1339ATI-1341Dose (mg/kg)53.94Cmax/Dose547370113(nM/(mg/kg))Tmax (h)24244AUC/Dose32232.1(nM*hr/(mg/kg))t<sub>1/2 </sub>(h)253116\nTABLE 17Pharmacokinetic Comparison of Three Fc-fused anti-myostatin AdnectinsPK ParametersPRD-1177PRD-1286PRD-1474Dose (mg/kg)222Clearance0.0170.0160.014(mL/min/kg)Vdss (L/kg)0.0930.1900.054t<sub>1/2 </sub>(h)68172"
    },
    {
        "molecule_name": "PRD-1286",
        "protein_target_name": "myostatin",
        "binding_metric": "Dose",
        "value": "2",
        "unit": "mg/kg",
        "is_logarithmic": false,
        "raw_mentions": "Here are the extracted sentences/rows that meet the criteria:\n\n\nThe biochemical HTRF IC50 was also plotted directly versus the NGS ER<sup>norm </sup>for each alanine mutant, as shown in FIG. 9.\nTABLE 16Pharmacokinetic Comparison of ThreePEGylated Formats for Adnectin 2987_H07PK ParametersATI-1338ATI-1339ATI-1341Dose (mg/kg)53.94Cmax/Dose547370113(nM/(mg/kg))Tmax (h)24244AUC/Dose32232.1(nM*hr/(mg/kg))t<sub>1/2 </sub>(h)253116\nTABLE 17Pharmacokinetic Comparison of Three Fc-fused anti-myostatin AdnectinsPK ParametersPRD-1177PRD-1286PRD-1474Dose (mg/kg)222Clearance0.0170.0160.014(mL/min/kg)Vdss (L/kg)0.0930.1900.054t<sub>1/2 </sub>(h)68172"
    },
    {
        "molecule_name": "PRD-1286",
        "protein_target_name": "myostatin",
        "binding_metric": "Clearance",
        "value": "0.016",
        "unit": "mL/min/kg",
        "is_logarithmic": false,
        "raw_mentions": "Here are the extracted sentences/rows that meet the criteria:\n\n\nThe biochemical HTRF IC50 was also plotted directly versus the NGS ER<sup>norm </sup>for each alanine mutant, as shown in FIG. 9.\nTABLE 16Pharmacokinetic Comparison of ThreePEGylated Formats for Adnectin 2987_H07PK ParametersATI-1338ATI-1339ATI-1341Dose (mg/kg)53.94Cmax/Dose547370113(nM/(mg/kg))Tmax (h)24244AUC/Dose32232.1(nM*hr/(mg/kg))t<sub>1/2 </sub>(h)253116\nTABLE 17Pharmacokinetic Comparison of Three Fc-fused anti-myostatin AdnectinsPK ParametersPRD-1177PRD-1286PRD-1474Dose (mg/kg)222Clearance0.0170.0160.014(mL/min/kg)Vdss (L/kg)0.0930.1900.054t<sub>1/2 </sub>(h)68172"
    },
    {
        "molecule_name": "PRD-1286",
        "protein_target_name": "myostatin",
        "binding_metric": "Vdss",
        "value": "0.190",
        "unit": "L/kg",
        "is_logarithmic": false,
        "raw_mentions": "Here are the extracted sentences/rows that meet the criteria:\n\n\nThe biochemical HTRF IC50 was also plotted directly versus the NGS ER<sup>norm </sup>for each alanine mutant, as shown in FIG. 9.\nTABLE 16Pharmacokinetic Comparison of ThreePEGylated Formats for Adnectin 2987_H07PK ParametersATI-1338ATI-1339ATI-1341Dose (mg/kg)53.94Cmax/Dose547370113(nM/(mg/kg))Tmax (h)24244AUC/Dose32232.1(nM*hr/(mg/kg))t<sub>1/2 </sub>(h)253116\nTABLE 17Pharmacokinetic Comparison of Three Fc-fused anti-myostatin AdnectinsPK ParametersPRD-1177PRD-1286PRD-1474Dose (mg/kg)222Clearance0.0170.0160.014(mL/min/kg)Vdss (L/kg)0.0930.1900.054t<sub>1/2 </sub>(h)68172"
    },
    {
        "molecule_name": "PRD-1286",
        "protein_target_name": "myostatin",
        "binding_metric": "t1/2",
        "value": "17",
        "unit": "h",
        "is_logarithmic": false,
        "raw_mentions": "Here are the extracted sentences/rows that meet the criteria:\n\n\nThe biochemical HTRF IC50 was also plotted directly versus the NGS ER<sup>norm </sup>for each alanine mutant, as shown in FIG. 9.\nTABLE 16Pharmacokinetic Comparison of ThreePEGylated Formats for Adnectin 2987_H07PK ParametersATI-1338ATI-1339ATI-1341Dose (mg/kg)53.94Cmax/Dose547370113(nM/(mg/kg))Tmax (h)24244AUC/Dose32232.1(nM*hr/(mg/kg))t<sub>1/2 </sub>(h)253116\nTABLE 17Pharmacokinetic Comparison of Three Fc-fused anti-myostatin AdnectinsPK ParametersPRD-1177PRD-1286PRD-1474Dose (mg/kg)222Clearance0.0170.0160.014(mL/min/kg)Vdss (L/kg)0.0930.1900.054t<sub>1/2 </sub>(h)68172"
    },
    {
        "molecule_name": "BMS-986089",
        "protein_target_name": "myostatin",
        "binding_metric": "Dose",
        "value": "2",
        "unit": "mg/kg",
        "is_logarithmic": false,
        "raw_mentions": "Here are the extracted sentences/rows that meet the criteria:\n\n\nThe biochemical HTRF IC50 was also plotted directly versus the NGS ER<sup>norm </sup>for each alanine mutant, as shown in FIG. 9.\nTABLE 16Pharmacokinetic Comparison of ThreePEGylated Formats for Adnectin 2987_H07PK ParametersATI-1338ATI-1339ATI-1341Dose (mg/kg)53.94Cmax/Dose547370113(nM/(mg/kg))Tmax (h)24244AUC/Dose32232.1(nM*hr/(mg/kg))t<sub>1/2 </sub>(h)253116\nTABLE 17Pharmacokinetic Comparison of Three Fc-fused anti-myostatin AdnectinsPK ParametersPRD-1177PRD-1286PRD-1474Dose (mg/kg)222Clearance0.0170.0160.014(mL/min/kg)Vdss (L/kg)0.0930.1900.054t<sub>1/2 </sub>(h)68172"
    },
    {
        "molecule_name": "BMS-986089",
        "protein_target_name": "myostatin",
        "binding_metric": "Clearance",
        "value": "0.014",
        "unit": "mL/min/kg",
        "is_logarithmic": false,
        "raw_mentions": "Here are the extracted sentences/rows that meet the criteria:\n\n\nThe biochemical HTRF IC50 was also plotted directly versus the NGS ER<sup>norm </sup>for each alanine mutant, as shown in FIG. 9.\nTABLE 16Pharmacokinetic Comparison of ThreePEGylated Formats for Adnectin 2987_H07PK ParametersATI-1338ATI-1339ATI-1341Dose (mg/kg)53.94Cmax/Dose547370113(nM/(mg/kg))Tmax (h)24244AUC/Dose32232.1(nM*hr/(mg/kg))t<sub>1/2 </sub>(h)253116\nTABLE 17Pharmacokinetic Comparison of Three Fc-fused anti-myostatin AdnectinsPK ParametersPRD-1177PRD-1286PRD-1474Dose (mg/kg)222Clearance0.0170.0160.014(mL/min/kg)Vdss (L/kg)0.0930.1900.054t<sub>1/2 </sub>(h)68172"
    },
    {
        "molecule_name": "BMS-986089",
        "protein_target_name": "myostatin",
        "binding_metric": "Vdss",
        "value": "0.054",
        "unit": "L/kg",
        "is_logarithmic": false,
        "raw_mentions": "Here are the extracted sentences/rows that meet the criteria:\n\n\nThe biochemical HTRF IC50 was also plotted directly versus the NGS ER<sup>norm </sup>for each alanine mutant, as shown in FIG. 9.\nTABLE 16Pharmacokinetic Comparison of ThreePEGylated Formats for Adnectin 2987_H07PK ParametersATI-1338ATI-1339ATI-1341Dose (mg/kg)53.94Cmax/Dose547370113(nM/(mg/kg))Tmax (h)24244AUC/Dose32232.1(nM*hr/(mg/kg))t<sub>1/2 </sub>(h)253116\nTABLE 17Pharmacokinetic Comparison of Three Fc-fused anti-myostatin AdnectinsPK ParametersPRD-1177PRD-1286PRD-1474Dose (mg/kg)222Clearance0.0170.0160.014(mL/min/kg)Vdss (L/kg)0.0930.1900.054t<sub>1/2 </sub>(h)68172"
    },
    {
        "molecule_name": "BMS-986089",
        "protein_target_name": "myostatin",
        "binding_metric": "t1/2",
        "value": "72",
        "unit": "h",
        "is_logarithmic": false,
        "raw_mentions": "Here are the extracted sentences/rows that meet the criteria:\n\n\nThe biochemical HTRF IC50 was also plotted directly versus the NGS ER<sup>norm </sup>for each alanine mutant, as shown in FIG. 9.\nTABLE 16Pharmacokinetic Comparison of ThreePEGylated Formats for Adnectin 2987_H07PK ParametersATI-1338ATI-1339ATI-1341Dose (mg/kg)53.94Cmax/Dose547370113(nM/(mg/kg))Tmax (h)24244AUC/Dose32232.1(nM*hr/(mg/kg))t<sub>1/2 </sub>(h)253116\nTABLE 17Pharmacokinetic Comparison of Three Fc-fused anti-myostatin AdnectinsPK ParametersPRD-1177PRD-1286PRD-1474Dose (mg/kg)222Clearance0.0170.0160.014(mL/min/kg)Vdss (L/kg)0.0930.1900.054t<sub>1/2 </sub>(h)68172"
    }
]